

Review

Target-Based Antiviral Drug Development Against Human Respiratory Viruses

Subodh Kumar Samrat ^{1,*}, Gauri Srivastava ^{1,†}, Ran Zhang ¹ , Zhong Li ¹ and Hongmin Li ^{1,2,3,4,*}¹ Department of Pharmacology and Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, 1703 E Mabel St, Tucson, AZ 85721, USA; gaurisri100@arizona.edu (G.S.)² Department of Chemistry & Biochemistry, College of Science & College of Medicine, The University of Arizona, Tucson, AZ 85721, USA³ The BIO5 Institute, The University of Arizona, Tucson, AZ 85721, USA⁴ Department of Molecular & Cellular Biology, College of Science, The University of Arizona, Tucson, AZ 85721, USA

* Correspondence: subodhsamrat@arizona.edu (S.K.S.); hli001@arizona.edu (H.L.); Tel.: +1-520-621-5789 (S.K.S.); +1-520-621-5728 (H.L.)

† These authors contributed equally to this work.

Abstract

Human respiratory viruses represent a major global health burden, causing millions of severe infections and deaths annually. Despite the central role of vaccines in prevention, their limitations, such as incomplete coverage, waning immunity, and vulnerability to viral evolution, underscore the urgent need for effective antiviral therapeutics. This review examines the principles and applications of target-based antiviral drug development against human respiratory viruses, emphasizing the identification and exploitation of conserved viral and host targets. Key viral proteins, including RNA-dependent RNA polymerases, proteases, and fusion glycoproteins, are analyzed across major virus families such as coronaviruses, paramyxoviruses, and adenoviruses, highlighting their structural features, functional constraints, and therapeutic potential. We further explore the integration of high-throughput screening and rational drug design, supported by advances in structural biology, cryo-electron microscopy, and computational approaches, including artificial intelligence-driven drug discovery. These methodologies collectively enhance the precision and efficiency of antiviral development. However, significant challenges remain, particularly the conflict between viral mutation and target conservation, the rapid emergence of drug resistance, and the safety limitations of host-targeted therapies. Finally, we discuss emerging strategies to overcome these barriers, including combination therapies and the development of broad-spectrum antivirals targeting conserved molecular mechanisms. This paper highlights a framework for the rational design of durable antiviral interventions capable of addressing both existing and emerging respiratory viral threats.

Academic Editors: Hiya Lahiri,
Jochen Bodem and Yuying Liang

Received: 17 June 2026

Revised: 4 August 2026

Accepted: 13 August 2026

Published: 27 August 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.**Keywords:** respiratory viruses; antiviral development; drug discovery; viral replication; coronavirus; respiratory syncytial virus (RSV); adenovirus; human parainfluenza virus (hPIV); measles; antiviral review

1. Introduction

Human respiratory viruses are among the most significant infectious disease threats due to their high transmissibility and capacity to cause severe lower respiratory tract infections (LRTIs). Acute lower respiratory tract infections (ALRTIs), many of which are viral, account for approximately 2.5 million deaths annually worldwide and are one

of the most common causes of deaths occurring in children under the age of five [1]. Among these pathogens, respiratory syncytial virus (RSV), influenza virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represent the greatest contributors to global morbidity and mortality.

This review focuses on the major human respiratory viruses for which antiviral drug development has achieved clinical success or demonstrates substantial therapeutic potential, including highly pathogenic and seasonal coronaviruses, influenza viruses, respiratory syncytial virus, rhinoviruses, human metapneumovirus, parainfluenza viruses, adenoviruses, and respiratory pathogens such as measles and rubella viruses. Together, these viruses account for a substantial proportion of global respiratory disease burden, encompass diverse viral families and replication strategies, and illustrate the range of viral targets currently being exploited for antiviral development. By comparing conserved molecular targets across these clinically important pathogens, this review highlights common principles underlying target-based antiviral discovery as well as virus-specific therapeutic challenges.

RSV is a leading cause of pediatric respiratory disease, responsible for an estimated 3.6 million hospitalizations and 100,000 deaths annually in children under five. In addition to pediatric populations, RSV poses a significant risk to the elderly, where its severity and hospitalization rates rival those of influenza [2].

Influenza virus remains a persistent global health challenge due to its ability to undergo antigenic drift and shift, resulting in seasonal epidemics and occasional pandemics. Annually, influenza causes 3–5 million cases of severe illness and between 290,000 and 650,000 deaths worldwide [3]. Historical pandemics, most notably the 1918 H1N1 outbreak, demonstrate the virus's capacity for rapid global spread and extreme mortality [4]. The continual evolution of influenza viruses necessitates frequent vaccine reformulation and contributes to antiviral resistance, underscoring the need for therapeutics that target highly conserved viral proteins such as neuraminidase, the cap-dependent endonuclease within the polymerase complex, and the M2 ion channel.

While endemic human coronaviruses are major contributors to seasonal respiratory infections worldwide, the emergence of SARS-CoV-2 further underscored the pandemic potential of respiratory viruses. As of 2026, COVID-19 has resulted in over 770 million confirmed cases [5] and more than 7 million deaths globally [5], with excess mortality estimates suggesting a substantially higher true burden. Beyond direct health effects, the pandemic exposed critical vulnerabilities in healthcare systems and highlighted the consequences of delayed therapeutic and vaccine responses.

Rhinoviruses, although typically associated with self-limiting upper respiratory tract infections, are the most common cause of the common cold and account for a substantial proportion of respiratory illnesses worldwide [6]. Their extensive genetic diversity and the absence of licensed antiviral therapies have hindered both vaccine and drug development, while their role in exacerbating asthma and chronic obstructive pulmonary disease highlights their considerable clinical and economic impact [7].

Although vaccines are central to prevention, their effectiveness is limited by several factors. Vaccines remain unavailable or provide incomplete protection for several clinically important respiratory viruses, including seasonal coronaviruses, RSV, parainfluenza virus, human metapneumovirus, and many rhinovirus and adenovirus strains [8]. Even when available, vaccine-induced immunity may be incomplete or short-lived, particularly in elderly or immunocompromised populations [9]. Additionally, vaccine development timelines leave populations vulnerable during emerging outbreaks, as demonstrated during the early stages of the COVID-19 pandemic. The emergence of immune-evasive variants, such as SARS-CoV-2 Omicron sub-lineages, further reduces vaccine effectiveness [10].

Given these limitations, antiviral therapeutics are essential for treating active infections, reducing disease severity, and limiting transmission. However, current antiviral options for respiratory viruses remain limited and often suboptimal.

For RSV, there is no widely used antiviral for routine clinical treatment. Ribavirin, the only FDA-approved option, has restricted use due to toxicity, teratogenicity, and limited efficacy [11,12]. Despite decades of investigation, there are currently no approved antiviral therapies for rhinovirus infection. Numerous experimental compounds targeting the viral capsid, 3C protease, and host factors required for replication have demonstrated antiviral activity; however, clinical translation has been limited by extensive viral diversity, rapid emergence of resistance, and insufficient efficacy [13]. Influenza antivirals, including neuraminidase inhibitors such as oseltamivir and zanamivir and the cap-dependent endonuclease inhibitor baloxavir marboxil, are most effective when administered early in infection and show reduced benefit beyond 48 h of symptom onset [13,14]. Resistance has also emerged, with oseltamivir-resistant H1N1 strains reported globally [15], highlighting the continued need for next-generation inhibitors targeting conserved viral proteins.

The COVID-19 pandemic accelerated antiviral development, resulting in agents such as remdesivir, molnupiravir, and nirmatrelvir-ritonavir (Paxlovid). Despite their impact, each has limitations: remdesivir requires intravenous administration and demonstrates modest mortality benefit [16,17]; molnupiravir raises concerns regarding mutagenicity [18,19]; and Paxlovid presents significant drug–drug interactions and reports of viral rebound [20,21]. These challenges highlight the need for more effective, accessible, and broadly active antiviral therapies.

Antiviral development has historically followed two primary approaches: non-specific and target-based strategies. Non-specific approaches include broad-spectrum antivirals and host-directed therapies, such as interferons or agents targeting host replication pathways. While these strategies may provide activity across multiple viruses, they are often limited by toxicity, off-target effects, and unpredictable efficacy. Ribavirin, for example, interferes with viral RNA synthesis but is associated with hemolytic anemia and teratogenicity [22]. Host-targeted therapies may reduce resistance risk but frequently disrupt essential cellular processes, limiting their clinical applicability [23,24].

In contrast, target-based antiviral development has emerged as the dominant paradigm. This approach focuses on selectively inhibiting viral proteins essential for replication, such as proteases, polymerases, and entry glycoproteins. Target-based antivirals offer improved specificity, reduced toxicity, and greater potential for rational optimization [25]. Advances in structural biology, including X-ray crystallography and cryo-electron microscopy, have enabled detailed characterization of viral proteins, facilitating structure-guided drug design.

Successful examples of this strategy include remdesivir and nirmatrelvir, SARS-CoV-2 main protease (Mpro) inhibitors [26–28]; influenza neuraminidase inhibitors (oseltamivir) [5,29,30] and cap-dependent endonuclease inhibitors (baloxavir marboxil [31,32]); and fusion inhibitors and polymerase inhibitors currently under investigation for RSV and other respiratory viruses [33]. These agents demonstrate the effectiveness of targeting conserved viral machinery, although resistance and strain variability remain ongoing challenges.

2. Overview of Respiratory Virus Classification and Therapeutic Landscape

2.1. Respiratory Virus Families

Human respiratory viruses comprise several genetically distinct viral families that differ in genome organization, replication strategy, and structural characteristics. Despite these differences, many exploit conserved molecular mechanisms that provide opportu-

nities for antiviral intervention. Figure 1 outlines the major respiratory virus families discussed throughout this review.




Figure 1. Taxonomic classification of the major human respiratory virus families discussed in this review. Respiratory viruses are classified into distinct viral families based on shared evolutionary relationships, genome organization, and replication strategies. The viruses included in this review comprise members of the *Coronaviridae*, *Orthomyxoviridae*, *Pneumoviridae*, *Paramyxoviridae*, *Picornaviridae*, *Adenoviridae*, and *Matonaviridae* families, encompassing the major respiratory pathogens and vaccine-preventable viruses considered in current antiviral development.

2.2. Approved Antiviral Therapies and Promising Investigational Compounds for Human Respiratory Viruses

The current antiviral landscape for respiratory viruses remains highly heterogeneous. While several viruses, including SARS-CoV-2, influenza virus, and respiratory syncytial virus (RSV), have multiple approved or authorized therapeutics targeting distinct stages of the viral life cycle, most other respiratory viruses continue to lack virus-specific antiviral treatments. Consequently, current management of many respiratory infections remains primarily supportive despite continued advances in target-based antiviral discovery. Table 1 summarizes currently registered or approved antiviral agents and biologics for human respiratory viruses, whereas Table 2 highlights promising investigational compounds that target conserved viral or host factors discussed throughout this review.

Table 1. Registered and approved antiviral therapies for human respiratory viruses. It summarizes currently registered or authorized antiviral agents and monoclonal antibodies together with their associated respiratory viruses and regulatory approval status.

Drug	Virus(es)	Regulatory Status/Approval
Remdesivir (Veklury)	SARS-CoV-2	FDA approved
Nirmatrelvir/ritonavir (Paxlovid)	SARS-CoV-2	FDA approved
Molnupiravir (Lagevrio)	SARS-CoV-2	FDA Emergency Use Authorization (U.S.); approved in several countries
Ensitrelvir (Xocova)	SARS-CoV-2	Fully approved in Japan; FDA approved for post-exposure prevention
Simnotrelvir	SARS-CoV-2	Approved in China
Leritrelvir	SARS-CoV-2	Approved in China
Palivizumab (Synagis)	RSV	FDA approved (high-risk infants)
Nirsevimab (Beyfortus)	RSV	FDA approved
Clesrovimab (Enflonsia)	RSV	FDA approved
Ribavirin	RSV	FDA approved
Oseltamivir (Tamiflu)	Influenza A & B	FDA approved
Zanamivir (Relenza)	Influenza A & B	FDA approved
Peramivir (Rapivab)	Influenza A & B	FDA approved
Baloxavir marboxil (Xofluza)	Influenza A & B	FDA approved
Amantadine	Influenza A	FDA approved, but no longer recommended because of widespread resistance
Rimantadine	Influenza A	FDA approved, but no longer recommended because of widespread resistance

Table 2. Promising investigation and repurposed compounds targeting human respiratory viruses. It summarizes representative investigational and repurposed antiviral compounds discussed throughout this review together with their associated respiratory viruses and current stage of development. The table highlights the diverse therapeutic strategies under investigation, including novel direct-acting antivirals, host-targeted approaches, and drug repurposing efforts aimed at expanding treatment options for respiratory viral infections.

Compound	Virus(es)	Current Development Stage/Status
GRL-0617	SARS-CoV-2	Preclinical
WEHI-P8	SARS-CoV-2	Preclinical
Bamlanivimab + Etesevimab	SARS-CoV-2	Former FDA Emergency Use Authorization (revoked)
Casirivimab + Imdevimab	SARS-CoV-2	Former FDA Emergency Use Authorization (revoked)
RFI-641	RSV	Preclinical
Lonafarnib	RSV	Preclinical
YM-254890	RSV	Preclinical
Lumicitabine (ALS-8176)	RSV	Clinical development discontinued (completed Phase II)
PC786	RSV	Phase II
Zelicapavir (EDP-938)	RSV	Phase II
RSV604	RSV	Phase II

Table 2. Cont.

Compound	Virus(es)	Current Development Stage/Status
Remdesivir *	hMPV	In silico repurposing candidate
Peramivir *	hMPV	In silico repurposing candidate
Prednisone *	hMPV	In silico repurposing candidate
DAS181 (Fludase)	HPIV	Phase III
Oseltamivir *	HPIV	Experimental repurposing candidate
Zanamivir *	HPIV	Experimental repurposing candidate
Experimental polymerase inhibitors	HPIV	Preclinical
Cidofovir *	Adenovirus	Off-label clinical use
Ganciclovir *	Adenovirus	Off-label clinical use
Brincidofovir	Adenovirus	Clinical development
Nelfinavir	Adenovirus	Preclinical
17-AAG	Adenovirus	Preclinical
mTOR inhibitors	Adenovirus	Preclinical
PTK inhibitors	Adenovirus	Preclinical
Ribavirin *	Measles virus	Off-label clinical use
Fusion inhibitor peptides (FIPs)	Measles virus	Preclinical
Nitazoxanide *	Rubella virus	Preclinical repurposing candidate
Amphotericin B *	Rubella virus	Preclinical repurposing candidate
Pleconaril	Rhinoviruses	Completed clinical trials; not approved
Rupintrivir	Rhinoviruses	Clinical development discontinued
Soluble ICAM-1 derivatives	Rhinoviruses	Clinical/investigational

* Repurposed compounds originally approved or developed for other indications.

3. Key Human Respiratory Viruses and Their Drug Targets

3.1. Coronaviruses

Coronaviruses, belonging to the family *Coronaviridae*, possess large (–30 kb), positive-sense RNA genomes encoding multiple structural and nonstructural proteins essential for replication and immune evasion (Figure 1) [34,35]. Recent structural reviews illuminate the architecture of key viral targets: spike (S), main protease (Mpro), papain-like protease (PLpro), and RNA-dependent RNA polymerase (RdRp). RdRp and Mpro are highly conserved, as their enzymatic functions are essential and their sequences remain largely unchanged across coronaviruses, making them attractive for broad-spectrum inhibitors (Table 3) [36–38]. In contrast, the spike (S) protein evolves rapidly under immune pressure and thus produces the fastest resistance (Table 3) [39,40]. High-value targets include RdRp and Mpro, whose well-defined, druggable pockets allow mechanism-based inhibition [36,41,42]. Surface-exposed S protein is readily accessible for antibodies or entry inhibitors, while intracellular enzymes like RdRp and the proteases require cell-permeable drugs [43–45]. In terms of structural dynamics, the S protein's unstable prefusion conformation complicates vaccine and inhibitor design [46,47], while the proteases are relatively rigid, facilitating structure-guided drug discovery [48,49].

In addition to the highly pathogenic coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2, four endemic human coronaviruses (HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1) circulate globally and are responsible for a substantial proportion of seasonal

upper respiratory tract infections [50]. These seasonal coronaviruses generally cause mild disease but can result in severe lower respiratory tract infections in older adults, infants, and immunocompromised individuals [50]. Although they differ in receptor usage, with HCoV-229E utilizing aminopeptidase N (APN), HCoV-NL63 binding ACE2, and HCoV-OC43 and HCoV-HKU1 recognizing 9-O-acetylated sialic acid receptors, their replication strategies remain highly conserved and rely on viral proteases (Mpro and PLpro) and RdRp for polyprotein processing and viral RNA synthesis [51]. Consequently, these conserved enzymes represent promising targets for broad-spectrum coronavirus therapeutics, whereas the more variable S protein primarily determines host tropism, receptor specificity, and immune escape.

High-resolution cryo-EM and X-ray crystallography have resolved SARS-CoV-2 spike (S) protein conformations in pre- and post-fusion states [52,53], enabling the design of entry inhibitors and vaccine antigens. Structural characterization of viral proteases Mpro and PLpro bound to inhibitors has similarly guided antiviral optimization, particularly through targeting active-site clefts to block replicase polyprotein processing. These insights underpin structure-guided drug design and mechanism-based inhibitor development.

Because structural characterization and antiviral development have been most extensively pursued for SARS-CoV-2, the following discussion focuses on COVID-19 as the best-characterized model for coronavirus antiviral drug discovery.

SARS-CoV-2 entry is mediated by S protein binding to ACE2, followed by proteolytic activation by TMPRSS2 or endosomal cathepsin L (Figure 2) [54–56]. Cleavage at the S1–S2 boundary and S2' site exposes fusion peptides that enable membrane fusion (Figure 2) [57,58]. Variations in S protein structure or cleavage efficiency can enhance transmissibility and immune evasion [59,60]. These mechanistic insights have informed updated vaccine designs, particularly stabilizing prefusion S conformations, and enabled development of entry inhibitors targeting ACE2–S interactions and host proteases [59].

COVID-19 therapeutics include direct-acting antivirals (DAAs), immunomodulators, and adjunctive treatments. DAAs target essential viral proteins such as RdRp, Mpro, PLpro, and the S protein, disrupting replication [61,62]. Remdesivir inhibits RdRp by acting as an adenosine nucleotide analog that causes delayed termination of viral RNA synthesis [63]; Molnupiravir, a nucleoside analog, inhibits RdRp by inducing error catastrophe through introducing mutations into the viral genome during RNA synthesis (Figure 3A) [64]. Because remdesivir competes with endogenous nucleotides during RNA synthesis, its antiviral activity depends on efficient intracellular conversion to the active triphosphate metabolite and sustained intracellular drug concentrations. Future optimization may therefore focus on improving oral bioavailability, tissue penetration, and resistance to viral proofreading mechanisms to enhance antiviral potency [65,66]. Nirmatrelvir targets Mpro by binding the catalytic active site and preventing cleavage of viral polyproteins required for replication (Figure 3B) [67]. The high degree of conservation within the Mpro catalytic site contributes to the broad antiviral potential of Mpro inhibitors. Ongoing efforts aim to improve binding affinity and maintain activity against resistance-associated substitutions arising within the protease active site [68]. Ensitrelvir (Xocova), another Mpro inhibitor, blocks viral polyprotein processing through inhibition of the main protease active site (Figure 3B), and became the first oral COVID-19 antiviral fully approved in Japan; additionally, it received FDA Fast Track designation and was recently approved by the U.S. FDA for post-exposure prevention of COVID-19 [69]. Structural optimization of next-generation Mpro inhibitors is directed toward enhancing potency, pharmacokinetic properties, and antiviral activity against newly emerging coronavirus variants [70]. Simnотrelvir and Ieritrelvir are orally administered SARS-CoV-2 main protease inhibitors that block proteolytic cleavage of viral polyproteins required for replication, thereby preventing the formation of the functional

replication-transcription complex; both have received approval in China for the treatment of COVID-19 [71,72]. Further optimization of this inhibitor class is focused on increasing target affinity and preserving efficacy against mutations that alter the protease active site while maintaining oral bioavailability [73,74]. PLpro-targeting compounds such as GRL-0617 and WEHI-P8 inhibit protease activity by binding near the catalytic site and preventing viral polyprotein processing and deubiquitinating functions required for efficient replication and immune evasion (Figure 3C) [75,76]. In addition to suppressing viral polyprotein processing, PLpro inhibition has been shown to restore host antiviral signaling by preventing viral deubiquitinating and deISGylating activities [77]. Current efforts are focused on improving inhibitor selectivity and cellular permeability while minimizing off-target inhibition of host deubiquitinases.




Figure 2. Viral replication cycle across different virus types. Viruses attach to host receptors, enter via membrane fusion or endocytosis, and release their genome; RNA viruses typically replicate in the cytoplasm using viral polymerases, while DNA viruses often utilize the nucleus and host machinery. Viral components are assembled into new virions and released through budding, exocytosis, or cell lysis depending on the virus type. Created in BioRender. Samrat, S. (2026) <https://BioRender.com/n4s8dze>.

In addition to DAAs, passive immunotherapies have been developed to target viral entry. The SARS-CoV-2 spike (S) protein is also targeted by neutralizing monoclonal antibody combinations including bamlanivimab plus etesevimab and casirivimab plus imdevimab, which bind the receptor-binding domain and block ACE2 interaction, thereby preventing viral attachment and entry into host cells (Figure 3D) [78]. Unlike DAAs, monoclonal antibodies function by extracellular neutralization of virions rather than inhibition of intracellular viral enzymes. Their clinical effectiveness is highly dependent on preservation of the targeted spike epitopes, making them particularly susceptible to loss of activity following antigenic drift [79]. Accordingly, the Emergency Use Authorizations for

bamlanivimab plus etesevimab and casirivimab plus imdevimab were revoked after the emergence of Omicron-lineage variants, which acquired spike mutations that substantially reduced neutralization efficacy [80]. Future antibody development focuses on broadly neutralizing antibodies directed against conserved epitopes and multispecific antibody combinations capable of maintaining efficacy against newly emerging variants.




Figure 3. SARS-CoV-2 viral targets and mechanisms of antiviral inhibition. (A) Spike (S) protein inhibitors. Monoclonal antibodies (bamlanivimab + etesevimab and casirivimab + imdevimab) that bind the receptor-binding domain of the S protein, blocking ACE2 interaction and preventing viral entry. (B) Main protease (Mpro) inhibitors. Nirmatrelvir inhibits Mpro by forming a reversible covalent bond with its catalytic cysteine, blocking polypeptide cleavage and halting complex replication formation. Ensitrelvir (Xocova) inhibits SARS-CoV-2 Mpro by blocking proteolytic cleavage of viral polyproteins required for replication. Mpro crystal is modified from PDB 6XHU. (C) Papain-like protease (PLpro) inhibitors. GRL0617 and WEHI-P8 inhibit PLpro by occupying its substrate-binding site, preventing deubiquitinating activity, impairing viral processing, and restoring host antiviral immune signaling. PLpro crystal structure is modified from PDB 7CMD. (D) RNA-dependent RNA polymerase (RdRp) inhibitors. Remdesivir inhibits RdRp by acting as an adenosine nucleotide analog that causes delayed termination of viral RNA synthesis. Molnupiravir induces error catastrophe by introducing mutations into the viral genome during RNA replication. Created in BioRender. Samrat, S. (2026) <https://BioRender.com/3ppvdpw> (A) and tz1y0gd (D left panel). ChemDraw Desktop (version 26.0; Revvity Signals Software, Inc., Waltham, MA, USA) was used to prepare the chemical structures, and PyMOL (version 3.1.8; Schrödinger, LLC, New York, NY, USA) was used to generate and visualize the crystal structures.

Among currently authorized therapies, Paxlovid (nirmatrelvir/ritonavir) and Veklury (remdesivir) have received FDA approval for the treatment of COVID-19 in eligible patients, while Lagevrio (molnupiravir) is available under Emergency Use Authorization (EUA) for certain adults with mild-to-moderate disease [81]. Immunomodulators (e.g., corticosteroids, IL-6 inhibitors) reduce hyperinflammation [82,83], while adjunctive therapies such as anticoagulants address complications like coagulopathy [84]. Emerging strategies include oligonucleotide-based therapies and next-generation vaccines. However, challenges remain, including antiviral resistance and heterogeneous patient responses.

Host-targeted antivirals (HTAs) represent an alternative approach by inhibiting host pathways required for viral replication, such as endosomal trafficking, protease activity, or immune signaling [85,86]. Because HTAs target conserved host processes rather than viral proteins, they generally impose a higher genetic barrier to resistance and may retain activity against newly emerging variants. Current efforts are focused on identifying host factors that are dispensable for normal cellular physiology but essential for viral replication [87]. While HTAs may offer broader activity and reduced resistance risk, their development is limited by potential toxicity and fewer late-stage clinical successes [85]. Avoiding disruption of essential host functions remains the primary barrier, though ongoing trials indicate continued potential.

Table 3. Comparison of key SARS-CoV-2 (coronavirus) viral targets based on sequence conservation, functional constraint, resistance rate, and broad-spectrum antiviral potential. It highlights that highly conserved and functionally essential enzymes like RdRp and Mpro show low resistance rates and strong broad-spectrum potential, whereas more variable proteins such as Spike and accessory proteins exhibit higher mutation tolerance and lower therapeutic robustness.

Viral Target	Sequence Conservation	Functional Constraint	Resistance Rate	Broad-Spectrum Potential	References
RdRp ⁱ	Very High	Essential catalytic enzyme; intolerant to mutations	Low	High	[88]
M ^{pro}	High	Required for polyprotein processing; conserved active site	Low–Moderate	High	[89,90]
PL ^{pro}	Moderate	Important but partially redundant; immune evasion roles	Moderate	Moderate	[91]
S	Low	Receptor binding tolerates mutations under immune pressure	High	Low	[92]
Accessory proteins	Very Low	Non-essential or host-specific functions	High	Very Low	[93]

3.2. Influenza Viruses

Human influenza viruses, of the family Orthomyxoviridae, possess segmented (~13.5 kb), negative-sense RNA genomes comprising eight gene segments that encode multiple structural and nonstructural proteins essential for viral entry, replication, assembly, and immune evasion (Figure 1) [94]. Recent structural studies have elucidated the architecture of key antiviral targets, including hemagglutinin (HA), neuraminidase (NA), the polymerase complex (PB1, PB2, and PA), and the matrix protein 2 (M2) ion channel. The polymerase complex and M2 are relatively conserved because their enzymatic functions are essential for viral replication, making them attractive targets for broad-spectrum antiviral development [95] (Table 4). In contrast, the surface glycoproteins HA and NA undergo continual antigenic drift under immune selection, requiring frequent vaccine reformulation and reducing susceptibility to immune-based therapies [96] (Table 4). High-value antiviral targets include the polymerase complex and NA, whose well-defined catalytic domains

enable mechanism-based inhibition (Table 4). Surface-exposed HA is readily accessible for antibodies or entry inhibitors, whereas intracellular targets such as the polymerase complex and M2 require cell-permeable small molecules [97,98]. In terms of structural dynamics, HA undergoes extensive conformational rearrangements during membrane fusion, complicating vaccine and inhibitor design, while the polymerase complex and NA possess relatively rigid catalytic domains that facilitate structure-guided drug discovery [99,100].

High-resolution cryo-EM and X-ray crystallography have resolved multiple conformational states of HA, NA, and the heterotrimeric polymerase complex, enabling the rational design of entry inhibitors, neuraminidase inhibitors, and polymerase-directed antivirals [101–103]. Structural characterization of the PA endonuclease active site, PB2 cap-binding domain, and NA catalytic pocket bound to inhibitors has similarly guided antiviral optimization by defining key drug-binding interactions required for inhibition of viral transcription and progeny virus release. These structural advances continue to support structure-guided drug discovery and mechanism-based antiviral development.

Influenza virus entry is initiated by HA binding terminal sialic acid residues on host cell glycoproteins, followed by receptor-mediated endocytosis. Endosomal acidification activates the M2 proton channel, promoting viral uncoating and triggering HA-mediated membrane fusion (Figure 2) [104]. Variations in HA receptor-binding specificity, fusion stability, and NA enzymatic activity contribute to viral transmissibility, host adaptation, and immune escape [105]. These mechanistic insights have informed updated vaccine designs targeting stabilized HA conformations and facilitated development of antivirals directed against HA, NA, the polymerase complex, and M2.

Influenza therapeutics include direct-acting antivirals (DAAs), supportive care, and adjunctive treatments. DAAs primarily target the viral polymerase complex, neuraminidase, and the M2 ion channel, thereby disrupting viral transcription, replication, and progeny virus release. Baloxavir marboxil inhibits the PA endonuclease by preventing cap-snatching, an essential step in viral mRNA synthesis (Figure 4A), while favipiravir acts as a nucleoside analog that is incorporated by the viral RNA polymerase, reducing replication fidelity and promoting lethal mutagenesis (Figure 4B) [106,107]. Because polymerase inhibitors target highly conserved enzymatic functions, they exhibit broad activity against influenza A and B viruses. However, resistance-associated substitutions within the PA endonuclease, particularly at residue I38, can reduce baloxavir susceptibility [108]. Current optimization efforts therefore focus on designing inhibitors that maintain high-affinity binding despite active-site substitutions and combining polymerase inhibitors with neuraminidase inhibitors to suppress resistance emergence [109]. Oseltamivir and zanamivir inhibit neuraminidase by binding its conserved catalytic pocket, preventing cleavage of terminal sialic acid residues and thereby blocking release of newly assembled virions (Figure 4C) [14]. Peramivir (Rapivab), an intravenously administered neuraminidase inhibitor, prevents progeny virion release by inhibiting the neuraminidase catalytic active site and is FDA-approved for the treatment of acute uncomplicated influenza (Figure 4C) [110,111]. Although neuraminidase inhibitors remain highly effective, substitutions such as H275Y reduce susceptibility to oseltamivir while preserving enzyme activity [112]. Consequently, next-generation neuraminidase inhibitors are being optimized to strengthen interactions with conserved catalytic residues outside common resistance hotspots and improve respiratory tissue retention. Adamantanes, a class of antiviral drugs that target the M2 ion channel of influenza A viruses, include Amantadine and rimantadine. They inhibit the M2 ion channel by blocking proton conductance required for viral uncoating (Figure 4D); however, widespread resistance among circulating influenza A viruses has largely eliminated their clinical utility [13,113]. Current efforts are therefore directed toward developing M2 inhibitors capable of retaining activity against resistant channel conformations.




Figure 4. Influenza viral targets and mechanisms of antiviral inhibition. (A) PA endonuclease inhibitor. Baloxavir marboxil inhibits the viral PA endonuclease by blocking the cap-snatching process required for viral mRNA transcription, thereby preventing viral protein synthesis. PA endonuclease crystal is modified from PBD 7N68. (B) RNA-dependent RNA polymerase (RdRp) inhibitor. Favipiravir inhibits viral RdRp by acting as a purine nucleoside analog that is incorporated into viral RNA, inducing lethal mutagenesis and impairing viral genome replication. (C) Neuraminidase inhibitors. Oseltamivir, zanamivir, and peramivir inhibit neuraminidase by binding to its active site, preventing cleavage of sialic acid residues and blocking the release of newly formed virions from infected cells. The influenza neuraminidase protein crystal is modified from PBD 9GQX. (D) M2 ion channel inhibitors. Amantadine and rimantadine inhibit the viral M2 proton channel, preventing endosomal acidification required for viral uncoating and release of the viral genome into the host cell. M2 Ion Channel crystal is modified from PBD 2L0J. Created in BioRender. Samrat, S. (2026) <https://BioRender.com/njwn37o> (B left panel).

In addition to DAAs, passive immunotherapeutic approaches targeting viral entry are under active investigation. Broadly neutralizing monoclonal antibodies directed against conserved epitopes within the HA stem inhibit the conformational changes required for membrane fusion, thereby preventing viral entry into host cells [114]. Unlike DAAs, these antibodies function through extracellular neutralization of virions rather than inhibition of intracellular viral enzymes. Because the HA stem is substantially more conserved than the immunodominant head domain, current development focuses on engineering broadly neutralizing antibodies with increased subtype breadth and prolonged serum half-life to improve protection against antigenically diverse influenza viruses.

Among currently approved therapies, oseltamivir, zanamivir, peramivir, and baloxavir marboxil are approved for treatment of influenza in appropriate clinical settings, whereas

adamantanes are no longer recommended because of widespread antiviral resistance [13]. Early antiviral administration substantially improves clinical outcomes, although the narrow therapeutic window and continual antigenic evolution remain significant challenges. Emerging strategies include universal influenza vaccines targeting conserved HA stem epitopes, next-generation polymerase inhibitors, and combination antiviral therapies designed to reduce resistance development.

Host-targeted antivirals (HTAs) represent an alternative strategy by inhibiting host pathways required for influenza replication, including endosomal trafficking, host proteases involved in HA activation, and nuclear import of viral ribonucleoproteins [115,116]. Because HTAs target conserved host processes rather than viral proteins, they generally impose a higher genetic barrier to resistance and may retain activity against newly emerging influenza strains [23]. Current efforts are focused on identifying host factors that are dispensable for normal cellular physiology but essential for viral replication. While HTAs may provide broader antiviral activity and reduced resistance risk, their development remains limited by concerns regarding host toxicity and disruption of essential cellular functions [117].

Table 4. Comparison of key antiviral targets in human influenza viruses based on sequence conservation, functional constraints, resistance rates, and broad-spectrum antiviral potential. It shows that the highly conserved polymerase complex and neuraminidase provide the strongest cross-strain coverage, whereas the more variable hemagglutinin and M2 ion channel exhibit higher rates of resistance and reduced therapeutic durability.

Viral Target	Sequence Conservation	Functional Constraint	Resistance Rate	Broad-Spectrum/Strain Coverage Potential	References
Polymerase complex (PB1, PB2, PA)	Very High	Required for viral transcription and replication	Low–Moderate	High (conserved across influenza A and B viruses)	[95,118]
Neuraminidase (NA)	High	Required for progeny virion release	Moderate	High	[119,120]
Hemagglutinin (HA)	Moderate	Essential for viral attachment and membrane fusion	High	Moderate	[97,121]
M2 ion channel	Moderate–High	Required for endosomal acidification and viral uncoating	Very High	Moderate (Influenza A only)	[122,123]
Accessory/nonstructural proteins	Low	Immune evasion; not required for viral replication	High	Low	[124]

3.3. Respiratory Syncytial Virus (RSV)

Respiratory syncytial virus (RSV) is a ubiquitous negative-sense RNA virus in the family Pneumoviridae, with a genome approximately 15.2 kb in length, and is a leading cause of lower respiratory tract infections in infants and young children (Figure 1) [125,126].

The virus targets epithelial cells of the upper and lower respiratory tract [127,128]. RSV possesses two major surface proteins: the fusion (F) protein and the attachment (G) protein, which coordinate host cell binding and membrane fusion [129]. Engagement of these proteins enables viral penetration and promotes cell–cell fusion, resulting in the formation of multinucleated syncytia that are readily observed *in vitro* and are a hallmark of RSV infection in cell culture, although their extent and contribution to disease pathogenesis *in vivo* remain incompletely defined [129–132]. Following entry, the large (L)

protein, which functions as the viral RNA-dependent RNA polymerase (RdRp), directs transcription and replication of the viral genome within the cytoplasm, making it necessary for viral propagation (Figure 2) [133,134]. The RSV nucleoprotein (N protein) encapsulates and protects the viral RNA genome while facilitating the formation of ribonucleoprotein complexes required for viral transcription and replication [135].

The fusion (F) protein is highly conserved, as it is critical for viral entry, whereas both F and the attachment (G) protein can mutate under antibody pressure, producing the fastest resistance (Table 5) [136–138]. The F protein and the N protein represent broad-spectrum targets, as their conserved sequence across RSV strains allows for vaccines or inhibitors to act widely (Table 5) [135,139,140]. High-value targets include F and N proteins, and the viral RNA polymerase (RdRp), which are essential for entry and replication, whereas the G protein is lower-value due to its variability and accessory immune-modulatory role [129,141]. Both F and G proteins are surface-exposed, making them accessible to neutralizing antibodies [129], while RdRp is intracellular and requires cell-permeable inhibitors [142]. The F protein's metastable prefusion conformation presents a structural challenge, necessitating stabilization for effective therapeutics (Table 5) [134,139].

Though natural infection with RSV elicits both humoral and cellular immune responses, immunity is incomplete and wanes over time [143–145]. This occurrence has complicated vaccine development, and treatment of RSV infection remains largely supportive [145]. Ribavirin is a guanosine nucleoside analog that inhibits RSV replication by interfering with viral RNA polymerase activity, depleting intracellular GTP pools, and inducing mutations that impair viral RNA synthesis and protein production [146]. Because ribavirin exerts antiviral activity through multiple complementary mechanisms, including lethal mutagenesis and depletion of nucleotide pools, resistance has remained relatively uncommon despite decades of clinical use [147]. However, its routine use is limited by uncertain clinical benefits, toxicity concerns, difficult administration, and high cost [148]. In addition to direct-acting antivirals, passive immunotherapies have been developed to prevent RSV infection. Palivizumab is a monoclonal antibody that targets the RSV fusion (F) protein, preventing viral attachment and membrane fusion with host cells, thereby inhibiting viral entry and F protein-mediated cell–cell fusion [149]. Unlike DAAs, palivizumab functions through extracellular neutralization of virions by stabilizing the prefusion conformation of the F protein rather than inhibiting intracellular viral replication. The monoclonal antibody represented the first targeted prophylaxis, reducing hospitalization risk in high-risk infants but is limited by high cost, monthly dosing, and modest effectiveness [150,151]. Recent advances include nirsevimab (Beyfortus), a long-acting monoclonal antibody that binds a highly conserved prefusion epitope on the RSV fusion (F) protein, blocking membrane fusion and preventing viral entry into host cells [152]. Its extended half-life is achieved through Fc engineering that enhances neonatal Fc receptor (FcRn)-mediated recycling, enabling sustained serum concentrations and season-long protection following a single dose [153]. It has been FDA-approved for all infants entering their first RSV season, offering broad population-level protection with a single intramuscular dose [154]. Additional RSV-directed therapeutics target both the fusion (F) and attachment (G) proteins. RFI-641 is a small-molecule fusion inhibitor that binds the F protein and blocks the membrane fusion process required for viral entry and F protein-mediated cell–cell fusion, in which preclinical studies demonstrated potent antiviral activity against RSV (Figure 5A) [155]. By preventing the conformational rearrangements of the prefusion F protein that drive membrane merger, fusion inhibitors act early in the viral life cycle and limit both initial infection and F protein-mediated cell–cell spread, which has been extensively demonstrated in vitro [156]. Lonafarnib, a farnesyltransferase inhibitor originally developed for other indications, has also been shown to interfere with F protein-mediated fusion and reduce

RSV replication in experimental models (Figure 5A) [157]. In contrast, YM-254890 targets host Gq-family G proteins involved in signaling pathways utilized during RSV infection, disrupting G protein-dependent viral processes and reducing viral propagation in vitro (Figure 5B) [158]. Because host-directed antivirals target cellular pathways rather than viral proteins, they may present a higher barrier to resistance, although maintaining selectivity and minimizing disruption of normal host signaling remain important considerations for clinical development.




Figure 5. RSV and hMPV viral targets and mechanisms of antiviral inhibition. (A) Fusion (F) protein inhibitors. RFI-641 inhibits the F protein by preventing the conformational changes required for membrane fusion, while lonafarnib impairs F protein-mediated fusion through inhibition of host-dependent prenylation pathways. (B) Attachment (G) protein inhibitors. YM-254890 inhibits G protein-mediated viral attachment by blocking Gq protein signaling pathways involved in viral entry. (C) Large polymerase (L) protein inhibitors. Lumicitabine (ALS-8176) inhibits the viral RNA-dependent RNA polymerase (L protein) by acting as a nucleoside analog, disrupting viral RNA synthesis and replication. (D) Nucleoprotein (N) inhibitors. Zelicapvir (EDP-938) and RSV604 inhibit the N protein by disrupting ribonucleoprotein complex formation, impairing viral transcription and replication. N protein crystal is modified from PDB 2YHM. Created in BioRender. Samrat, S. (2026) <https://BioRender.com/5gvemxd> (A left panel), ky8wff0 (B left panel) and 1iixuej (C left panel).

The viral RNA-dependent RNA polymerase (L protein) and nucleoprotein (N protein) are significant antiviral targets as well. Lumicitabine (ALS-8176) inhibits L protein polymerase activity by inducing premature termination of viral RNA synthesis [159], while PC786 acts as an inhaled polymerase inhibitor that suppresses RSV replication (Figure 5C) [160]. The N protein has also emerged as a promising antiviral target, with Zelicapavir (EDP-938) disrupting nucleoprotein-dependent replication complex formation [161] and RSV604 interfering with nucleocapsid functions essential for viral transcription and replication (Figure 5D) [162]. Because nucleoprotein oligomerization and ribonucleoprotein complex assembly are highly conserved and indispensable for genome replication, N protein inhibitors may retain activity across diverse RSV strains.

Currently, ribavirin, palivizumab (Synagis), nirsevimab (Beyfortus), and recently approved clesrovimab (Enflonsia) for infants are the only FDA-approved RSV-directed therapeutics, whereas fusion inhibitors, polymerase inhibitors, and nucleoprotein inhibitors remain under clinical or preclinical investigation [163].

Despite persistent challenges in RSV antiviral development, advances in high-throughput screening and computational modeling have significantly accelerated RSV antiviral discovery by improving target identification, lead optimization, and mechanism-based drug design. For example, high-resolution structural characterization of the RSV prefusion F protein enabled the rational development of the monoclonal antibody nirsevimab, marking significant progress in RSV prevention and treatment [139].

3.4. Human Metapneumovirus (hMPV)

Human metapneumovirus (hMPV), a member of the *Paramyxoviridae* family and closely related to respiratory syncytial virus (RSV), is a negative-sense single-stranded RNA virus that causes respiratory illnesses, including bronchiolitis and pneumonia [164]. The hMPV genome is approximately 13 kb in length and encodes nine proteins (Figure 1) [165].

Of these, hMPV virions possess two key surface glycoproteins: the attachment protein (G) and the fusion protein (F). The G protein facilitates binding to host cell receptors, while the F protein mediates fusion of the viral envelope with the host cell membrane [166]. The F protein is highly conserved, as it is required for membrane fusion [167,168], whereas the G protein mutates under immune pressure, producing the fastest resistance (Table 5) [169,170]. Both F and the viral polymerase are broad-spectrum targets, as they are conserved across hMPV strains and amenable to inhibitors [171,172]. High-value targets include F and polymerase, which are essential for entry and replication, while the G protein is low-value due to its accessory role. The F protein is surface-exposed and accessible to antibodies or inhibitors [173], whereas the polymerase is intracellular and requires drugs that can cross cell membranes [174]. Additionally, the F protein's prefusion conformation is metastable, complicating inhibitor or vaccine design (Table 5) [175].

Once inside the cytoplasm, the viral RNA-dependent RNA polymerase (RdRp) transcribes the genome, producing viral mRNA and replicating the viral RNA [176,177]. Viral particles are assembled in the cytoplasm and released through cell lysis [176,178]. The virus can also induce syncytia formation, contributing to tissue pathology, a phenomenon well documented in vitro; however, its frequency and contribution to tissue pathology during human infection remain less well established [165,179]. The virus's pathogenesis involves evasion of host immune responses; for example, the G protein can inhibit innate immune signaling, allowing efficient viral replication and disease progression [180,181].

No HMPV-specific monoclonal antibodies have reached Phase 3 clinical trials, nor do any FDA-approved antiviral agents specifically target hMPV [182,183]. However, recent studies have identified several FDA-approved drugs that may be repurposed for HMPV treatment. Notably, in an in silico molecular docking study, remdesivir and peramivir were

predicted to bind to the hMPV fusion (F) protein, with calculated binding affinities of -9.5 kcal/mol and -9.2 kcal/mol, respectively [183,184]. These computational findings provide preliminary support for drug repurposing but require experimental validation to confirm antiviral activity and therapeutic efficacy against hMPV.

To address the significant challenges that remain in hMPV antiviral development, including the absence of approved therapeutics and incomplete understanding of viral entry mechanisms, drug repurposing strategies have accelerated candidate discovery by leveraging existing safety and pharmacokinetic data. For instance, given the close phylogenetic relationship between RSV and hMPV, a recent computational drug-repurposing study identified the FDA-approved asthma drug prednisone as a potential hMPV therapeutic through its predicted interaction with Toll-like receptor 4 (TLR4) [185].

Table 5. Summary of key respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) drug targets by comparing their sequence conservation, functional constraints, resistance rates, and breadth of antiviral coverage. It shows that highly conserved, replication-essential proteins like RdRp/L protein and the F fusion protein offer the strongest broad-spectrum potential, while variable attachment and accessory proteins are more prone to resistance and have limited therapeutic coverage.

Viral Target	Sequence Conservation	Functional Constraint	Resistance Rate	Broad-Spectrum/Strain Coverage Potential	References
F protein	High	Essential for viral entry and membrane fusion; intolerant to major structural changes	Moderate–High (mutates under antibody pressure)	High (conserved across RSV A and B strains)	[186]
RdRp/L protein	Very High	Required for transcription and replication of viral genome	Low	High	[187]
N protein	High	Essential for nucleocapsid formation, viral RNA encapsidation, and assembly of the transcription/replication complex; mutations are often poorly tolerated.	Low	High	[188]
G protein	Low	Accessory role in attachment and immune modulation; non-essential for replication	High	Low	[169,189]
Accessory proteins	Low–Moderate	Immune evasion; not strictly required for viral replication	High	Low	[186]

3.5. Parainfluenza Viruses (HPIVs)

Human parainfluenza viruses (HPIVs) are enveloped, negative-sense single-stranded RNA viruses belonging to the family *Paramyxoviridae*, genus *Respirovirus* (HPIV-1 and HPIV-3) and *Rubulavirus* (HPIV-2 and HPIV-4 [190]). The HPIV genome is approximately 15–19 kb in length, encoding six major structural proteins and several accessory proteins [191]. The two key surface glycoproteins are hemagglutinin neuraminidase (HN) and fusion protein (F), both critical to viral entry and pathogenesis. HN mediates attachment to host cells by binding sialic acid-containing glycoconjugates, while also possessing neuraminidase activity to facilitate virion release and prevent self-aggregation [191,192]. Following receptor binding, the F protein undergoes changes triggered by HN interaction, driving fusion of the viral envelope with the host cell membrane (Figure 2) [193,194].

From a therapeutic standpoint, the F protein is highly conserved and essential for viral entry [195], while HN mutates moderately under selective pressure, producing relatively fast resistance (Table 6) [196]. Both F and the viral polymerase are broad-spectrum targets, as they are functionally conserved across HPIV types (Table 6). High-value targets include F and polymerase, critical for entry and replication, whereas HN is considered low-value due to its bifunctional nature, which complicates drug targeting. The F protein is surface-exposed and accessible to neutralizing antibodies, whereas the polymerase is intracellular and requires cell-permeable inhibitors [197]. Additionally, the F protein undergoes significant conformational changes during prefusion-to-postfusion rearrangement, which must be considered in vaccine or inhibitor design (Table 6) [198,199].

Structural and computational studies have significantly advanced antiviral development against HPIV by elucidating the architecture and function of the hemagglutinin-neuraminidase (HN) and fusion (F) glycoproteins, and the integration of high-throughput screening has enabled the rapid identification and optimization of antiviral candidates with improved specificity and potency against HPIV. X-ray crystallography, for example, was used to resolve the structure of the HPIV hemagglutinin-neuraminidase (HN) protein in complex with receptor analogs and inhibitors, enabling the rational design of neuraminidase inhibitors such as BCX2798 and BCX2855 [200].

Despite decades of research, there are currently no FDA-approved antivirals for HPIV infection, and treatment remains largely supportive [201,202]. Nevertheless, several viral proteins present attractive opportunities for therapeutic intervention. Among these, the blocking of HPIV fusion (F) protein activation has been the most extensively studied. One of the most advanced candidates, DAS181 (fludase), is a recombinant sialidase that removes sialic acid receptors from the airway epithelium, thereby preventing viral attachment [203,204]. By targeting a host receptor rather than a viral protein, DAS181 is less susceptible to the emergence of resistance caused by viral mutations. Future optimization is focused on improving localized airway retention while minimizing desialylation of non-target respiratory tissues to preserve normal epithelial function.

Additional therapeutic strategies have targeted the hemagglutinin-neuraminidase (HN) protein. Oseltamivir (Tamiflu), a neuraminidase inhibitor widely used against influenza viruses, has demonstrated inhibitory activity against HPIV HN protein function in experimental studies, reducing viral spread by blocking receptor cleavage and virion release (Figure 6) [200]. Similarly, zanamivir targets the HN neuraminidase active site, preventing sialic acid cleavage and impairing viral propagation (Figure 6) [205]. Because the HN protein coordinates receptor binding, neuraminidase activity, and activation of the fusion protein, its inhibition simultaneously disrupts multiple steps of the viral entry process. Structure-guided optimization of HN inhibitors is therefore directed toward increasing affinity for the conserved catalytic pocket while maintaining activity against sequence variation among HPIV serotypes. Although neither oseltamivir nor zanamivir is FDA-approved for HPIV infection, both compounds have served as important tools for investigating HN-directed antiviral strategies and the development of next-generation HPIV therapeutics.

The viral RNA polymerase complex, composed of the large (L) protein in association with phosphoprotein (P) and nucleoprotein (N), also represents a logical drug target. This complex directs genome replication and transcription, and inhibition at this stage could block viral propagation [206,207]. Because the L protein contains highly conserved catalytic domains that are indispensable for RNA synthesis, polymerase inhibitors may exhibit activity across multiple HPIV serotypes and potentially other members of the *Paramyxoviridae* family. Nucleoside analogues and other polymerase inhibitors have demonstrated activity in vitro, but most remain in preclinical stages or very early clinical testing [208].

Current efforts are focused on developing polymerase inhibitors with improved selectivity for the viral polymerase over host polymerases, enhanced intracellular activation of nucleoside analogs, and favorable pharmacokinetic properties that support effective drug concentrations within the respiratory epithelium.




Figure 6. hPIV viral targets and mechanisms of antiviral inhibition. Oseltamivir and zanamivir inhibit Hemagglutinin-neuraminidase (HN) protein activity by binding the active site and blocking sialic acid cleavage, preventing viral release. HN protein crystal is modified from PDB 8TQI.

Table 6. Summary of key human parainfluenza virus (hPIV) drug targets based on sequence conservation, functional constraint, resistance rate, and broad-spectrum antiviral potential. It highlights that highly conserved and essential enzymes like RdRp/L protein and the F fusion protein offer the strongest broad coverage across hPIV types, whereas more variable proteins such as HN and accessory proteins exhibit higher resistance risk and lower therapeutic robustness.

Viral Target	Sequence Conservation	Functional Constraint	Resistance Rate	Broad-Spectrum/Strain Coverage Potential	References
F protein	High	Essential for viral entry and membrane fusion; intolerant to major structural disruption; fusion occurs at neutral pH	Low–Moderate	High (conserved across HPIV types 1–4)	[195,209]
RdRp/L protein	Very High	Required for transcription and genome replication	Low	High	[210]
HN protein	Moderate	Bifunctional: mediates attachment and receptor-cleaving activity; complicates drug targeting	Moderate–High	Moderate–Low	[211]
Accessory proteins	Low–Moderate	Facilitate immune evasion or replication efficiency; not strictly required	High	Low	[212]

3.6. Measles & Rubella Viruses

Measles virus (MeV) is an enveloped, negative-sense single-stranded RNA virus belonging to the family *Paramyxoviridae*, genus *Morbillivirus* (Figure 1) [213]. The measles virus genome is approximately 15.9 kb in length and encodes six major structural proteins [213–215]. Viral entry is mediated by the hemagglutinin (H) protein, which binds the signaling lymphocyte activation molecule (SLAM/CD150) on immune cells [216–218] while the fusion (F) protein facilitates membrane fusion and viral penetration (Figure 2) [213]. Although measles and rubella are transmitted primarily through respiratory droplets and aerosols, they are not strictly classified as respiratory viruses because their primary patho-

genesis is systemic rather than being confined to the respiratory tract. Following initial replication in the respiratory epithelium, both viruses disseminate throughout the body, causing multisystem disease. Rubella virus (RuV) is an enveloped, positive-sense single-stranded RNA virus of the *Matonaviridae* (previously *Togaviridae*) family and is the causative agent of rubella (German measles) [219–221]. The rubella virus genome is approximately 9.8 kb in length and encodes two nonstructural proteins (P150 and P90) involved in viral replication and three structural proteins [222]. The rubella virus envelope glycoproteins E1 and E2 enable viral entry into host cells, with E1 mediating membrane fusion and E2 supporting attachment, assembly, and proper glycoprotein function (Figure 2) [223]. Specifically, viral entry occurs via receptor-mediated endocytosis, followed by cytoplasmic replication, where viral RNA serves directly as mRNA for translation of viral proteins (Figure 2) [224–226].

The F protein in measles and the E1 protein in rubella is highly conserved and essential for viral entry [213,227–229], making them high-value targets. Surface glycoproteins such as H (MeV) and E1 (Rubella) are accessible to neutralizing antibodies but can mutate under immune pressure, resulting in fast resistance [229,230]. Viral polymerases are broadly conserved across these virus families, offering additional high-value, broad-spectrum targets, although they are intracellular and require cell-permeable inhibitors [231,232]. The F protein's metastable prefusion conformation introduces challenges for inhibitor design, highlighting the need to consider protein dynamics in therapeutic development (Table 7) [233].

Although measles is preventable through the combined measles-mumps-rubella (MMR) vaccine [13], outbreaks continue to occur, primarily due to vaccine hesitancy or gaps in immunization coverage [234]. Currently, there are no FDA-approved antivirals for measles, though ribavirin has been studied in severe cases and immunocompromised patients, demonstrating limited efficacy. Ribavirin exerts antiviral activity through multiple complementary mechanisms, including inhibition of viral RNA synthesis, depletion of intracellular GTP pools, and induction of lethal mutagenesis, although these effects have not translated into consistent clinical benefit against measles virus. Fusion inhibitor peptide (FIP) derivatives inhibit measles virus infection by binding to the viral fusion (F) protein and preventing the membrane fusion events required for viral entry into host cells (Figure 7A); however, these peptides remain experimental and have not received FDA approval for clinical use [235]. By stabilizing the prefusion conformation of the F protein, these peptides prevent the structural rearrangements required for fusion of the viral and host cell membranes, thereby blocking infection at an early stage of the viral life cycle [236]. Future optimization is focused on increasing peptide stability, extending serum half-life, and improving delivery to the respiratory tract to enhance antiviral activity in vivo.

Like measles, rubella is preventable through the MMR vaccine [237], and there are no specific antiviral therapies available [237]. Several compounds have been investigated for their ability to disrupt the function of the rubella virus envelope glycoproteins E1 and E2. While nitazoxanide (NTZ), an FDA-approved drug for parasitic infections, has demonstrated broad-spectrum antiviral activity, including against rubella virus in laboratory settings, it is not approved for use against rubella in clinical practice (Figure 7B) [238]. Nitazoxanide (NTZ) inhibits rubella virus replication by disrupting host-mediated maturation and trafficking of the viral envelope glycoproteins E1 and E2, thereby impairing viral assembly and infectivity [238]. Because NTZ targets host pathways involved in viral protein maturation rather than viral enzymes directly, it may present a higher barrier to resistance than conventional direct-acting antivirals. Future development of NTZ-derived compounds is aimed at improving antiviral potency while preserving selectivity for host pathways that are preferentially exploited during viral infection. Another compound,

amphotericin B (Fungizone), has been shown to inhibit rubella virus infection by altering membrane integrity and disrupting envelope-mediated fusion processes associated with E1 and E2 activity (Figure 7B) [239]. Further investigation is needed to identify derivatives that retain antiviral activity while minimizing the dose-limiting toxicity associated with amphotericin B. Although neither agent is approved for the treatment of rubella, both have provided valuable insights into E1/E2-directed antiviral strategies and potential host-targeted therapeutic approaches.




Figure 7. Measles and Rubella viral targets and mechanisms of antiviral inhibition. (A) Measles Fusion (F) protein inhibitor. Fusion inhibitor peptides (FIP) inhibit the F protein by binding to its heptad repeat regions, preventing the conformational changes required for membrane fusion and viral entry into host cells. FIP crystal is modified from PDB 5YZD. (B) Rubella envelope protein E1/E2 inhibitors. Nitazoxanide disrupts host-mediated glycoprotein maturation, impairing E1/E2 function, while amphotericin B (Fungizone) alters membrane integrity, reducing viral entry and fusion. Created in BioRender. Samrat, S. (2026) <https://BioRender.com/5gvemxd> (A left panel) and xr2a0ho (B left panel).

Given the absence of approved antivirals and the continued occurrence of outbreaks, alternative approaches such as drug repurposing, host-targeted therapies, and fusion protein-directed inhibitors are being investigated to expand treatment options. These efforts are increasingly supported by high-throughput screening and computational drug discovery platforms, which improve the speed and precision of antiviral candidate identification.

Overall, measles and rubella remain critical targets for immunization programs due to their high transmissibility and, in the case of rubella, severe congenital consequences. Vaccination remains the primary intervention, with research efforts continuing towards antiviral development.

Table 7. Comparison of key viral targets in measles and rubella based on sequence conservation, functional constraints, resistance rates, and broad-spectrum antiviral potential. It shows that highly conserved, replication-essential polymerases and fusion proteins (MeV F and Rubella E1) provide the strongest cross-strain coverage, while more variable surface attachment and accessory proteins exhibit higher resistance and lower therapeutic durability.

Viral Target	Sequence Conservation	Functional Constraint	Resistance Rate	Broad-Spectrum/Strain Coverage Potential	References
F protein (MeV)	High	Essential for viral entry and membrane fusion; metastable prefusion conformation	Moderate–High (mutates under immune pressure)	High	[240,241]
E1 protein (Rubella)	High	Required for viral entry and membrane fusion	Moderate–High	High	[223]
Viral polymerases (MeV & Rubella)	Very High	Required for viral transcription and replication	Low	High (conserved across strains)	[45,214]
Attachment glycoproteins (H protein- MeV)	Moderate	Mediates host receptor binding (SLAM/CD150); surface-exposed	High	Moderate	[242]
Accessory proteins	Low	Non-essential or redundant roles	High	Low	[243]

3.7. Rhinoviruses (HRVs)

Human rhinoviruses (HRVs), belonging to the family *Picornaviridae*, possess small (~7.2 kb), positive-sense single-stranded RNA genomes that encode a single polyprotein processed into structural and nonstructural proteins essential for viral entry, replication, and immune evasion (Figure 1) [244]. Recent structural studies have elucidated the architecture of key antiviral targets, including the capsid protein VP1, the 3C protease (3Cpro), the RNA-dependent RNA polymerase (3Dpol), and host cell receptors involved in viral attachment. The 3C protease and 3D polymerase are highly conserved because their enzymatic functions are essential for viral replication, making them attractive targets for broad-spectrum antiviral development (Table 8) [245]. In contrast, the surface-exposed capsid proteins exhibit substantial sequence diversity across more than 160 rhinovirus serotypes, limiting the durability of capsid-directed therapies and vaccine development (Table 8) [246]. High-value antiviral targets include 3Cpro and 3Dpol, whose conserved catalytic domains enable mechanism-based inhibition (Table 8) [245,247,248]. Surface-exposed VP1 is readily accessible for entry inhibitors, whereas intracellular enzymes such as 3Cpro and 3Dpol require cell-permeable small molecules [249]. In terms of structural dynamics, the viral capsid undergoes conformational rearrangements during receptor binding and uncoating, complicating the design of broadly active entry inhibitors, while the protease and polymerase possess relatively rigid catalytic sites that facilitate structure-guided drug discovery (Table 8) [250,251].

High-resolution X-ray crystallography and cryo-EM have resolved multiple conformational states of the rhinovirus capsid, 3C protease, and RNA-dependent RNA polymerase, enabling the rational design of capsid-binding compounds and enzyme-directed antivirals [250,252]. Structural characterization of VP1 hydrophobic pockets and the catalytic sites of 3Cpro and 3Dpol bound to inhibitors have similarly guided antiviral optimization by defining key drug-binding interactions required for inhibition of viral entry and replication [249,253]. These structural advances continue to support structure-guided drug discovery and mechanism-based antiviral development.

Rhinovirus entry is initiated by binding of the viral capsid to host receptors, most commonly intercellular adhesion molecule-1 (ICAM-1) for major-group rhinoviruses and low-density lipoprotein receptor (LDLR) family members for minor-group viruses, followed by receptor-mediated endocytosis [254]. Receptor engagement induces conformational changes within the capsid that promote viral uncoating and release of the viral RNA genome into the cytoplasm (Figure 2). Variations in receptor usage and capsid structure contribute to host tropism, transmission, and immune evasion [255]. These mechanistic insights have informed the development of capsid-binding antivirals and receptor-targeted strategies designed to prevent viral attachment and entry.

Rhinovirus therapeutics remain largely investigational, with direct-acting antivirals primarily targeting the viral capsid, 3C protease, and RNA-dependent RNA polymerase. Pleconaril binds a hydrophobic pocket within VP1, stabilizing the viral capsid and preventing the conformational changes required for receptor attachment and uncoating (Figure 8A) [256]. Although pleconaril demonstrated antiviral activity in clinical trials, variable efficacy across rhinovirus serotypes and drug interactions limited its clinical approval [257,258]. Current optimization efforts focus on developing capsid inhibitors that retain activity across diverse serotypes by targeting highly conserved structural features of the VP1 pocket while improving pharmacokinetic properties. Rupintrivir inhibits 3C protease by binding the catalytic active site and preventing cleavage of the viral polyprotein required for formation of the replication complex (Figure 8B) [6,253]. Because the catalytic residues of 3Cpro are highly conserved among picornaviruses, protease inhibitors possess broad-spectrum antiviral potential. However, limited bioavailability and suboptimal clinical efficacy have restricted their development [259]. Current efforts therefore focus on improving oral bioavailability, increasing intracellular drug exposure, and enhancing binding interactions with conserved residues surrounding the catalytic site to maintain activity against genetically diverse rhinoviruses.




Figure 8. Rhinovirus viral targets and mechanisms of antiviral inhibition. (A) VP1 coat protein inhibitor. Pleconaril inhibits the VP1 coat protein by binding to a hydrophobic pocket within the capsid, stabilizing its structure and preventing receptor binding, viral uncoating, and genome release. VP1 coat protein crystal is modified from PBD 1AYM. (B) 3C Protease inhibitor. Rupintrivir inhibits the viral 3C protease by binding to its catalytic active site, preventing cleavage of the viral polyprotein into functional proteins required for viral replication. 3C protease crystal is modified from PBD 6KU8.

In addition to DAAs, host-targeted strategies have been investigated to inhibit viral attachment and replication. Soluble ICAM-1 derivatives and receptor-blocking compounds prevent viral binding to host cells by competitively inhibiting interactions between the viral capsid and cellular receptors [260,261]. Unlike capsid-binding antivirals, these approaches target conserved host factors rather than viral proteins and may therefore reduce the likelihood of resistance development. However, their clinical application remains limited by incomplete coverage of all rhinovirus receptor groups and challenges associated with efficient delivery to the respiratory epithelium [262]. Currently, no antiviral therapies have received FDA approval for the treatment of rhinovirus infection, and clinical management remains primarily supportive [13]. The extensive antigenic diversity of rhinoviruses, together with the large number of circulating serotypes, has hindered both antiviral and vaccine development. Emerging strategies therefore focus on broad-spectrum inhibitors directed against conserved viral enzymes, next-generation capsid inhibitors with improved serotype coverage, and host-targeted approaches capable of limiting viral entry while minimizing toxicity.

Host-targeted antivirals (HTAs) represent an alternative strategy by inhibiting host pathways required for rhinovirus replication, including receptor-mediated viral attachment, endosomal trafficking, and intracellular signaling pathways that support viral replication [263,264]. Because HTAs target conserved host processes rather than highly variable viral capsid proteins, they generally impose a higher genetic barrier to resistance and may retain activity against numerous rhinovirus serotypes. Current efforts are focused on identifying host factors that are dispensable for normal cellular physiology but essential for viral replication [264]. While HTAs may provide broader antiviral activity and reduced resistance risk, their development remains limited by concerns regarding host toxicity and disruption of essential cellular functions.

Table 8. Comparison of key antiviral targets in human rhinoviruses based on sequence conservation, functional constraints, resistance rates, and broad-spectrum antiviral potential. It shows that the highly conserved 3C protease and RNA-dependent RNA polymerase provide the strongest cross-serotype coverage, whereas the structurally diverse capsid protein VP1 exhibits higher resistance potential and reduces therapeutic durability.

Viral Target	Sequence Conservation	Functional Constraint	Resistance Rate	Broad-Spectrum/Strain Coverage Potential	References
3C protease (3Cpro)	Very High	Required for viral polyprotein processing	Low	High	[245,265]
RNA-dependent RNA polymerase (3Dpol)	Very High	Required for viral RNA transcription and replication	Low	High	[248,251]
Capsid protein VP1	Moderate	Required for viral attachment and uncoating	High	Moderate	[266,267]
Host receptors (ICAM-1/LDLR)	High	Required for viral attachment and entry	Low	High	[252,268]
Accessory / nonstructural proteins	Low	Immune evasion and host interactions	High	Low	[262]

3.8. Adenoviruses (AdVs)

Adenoviruses (AdVs) are non-enveloped, double-stranded DNA viruses belonging to the family Adenoviridae (Figure 1). They possess an icosahedral capsid and a genome approximately 30–40 kilobases in length, encoding over 40 proteins [269,270]. There are more than 50 human serotypes classified into seven species (A–G), with AdV types 1, 2, 3, 4, and 5 being most commonly associated with human disease [270,271]. Clinically, they cause a range of illnesses, including upper and lower respiratory tract infections, conjunctivitis, gastroenteritis, and cystitis [272]. AdV replication occurs exclusively in the host cell nucleus [273]. The viral lifecycle begins with the attachment of the fiber protein to the coxsackievirus and adenovirus receptor (CAR) on the host cell surface (Figure 2) [273–275]. This binding facilitates clathrin-mediated endocytosis, leading to the internalization of the virus [273,276,277].

The DNA polymerase is highly conserved and essential for viral genome replication, making it a high-value target (Table 9) [278,279]. In contrast, early regulatory proteins such as E1A and E2A, as well as fiber protein, are lower-value targets due to variability or complex cellular interactions [280]. The fiber protein is surface-exposed and accessible to neutralizing antibodies, whereas DNA polymerase is intracellular and requires cell-permeable inhibitors [270,281]. Broad-spectrum strategies could target the polymerase or host factors critical for replication across multiple adenovirus serotypes (Table 9). Compared to paramyxoviruses, adenovirus capsids are structurally stable, simplifying drug targeting relative to viruses with dynamic fusion proteins [282,283].

No FDA-approved antiviral agents specifically target adenoviruses (AdVs) [284]. In immunocompromised patients, some antivirals have been used off-label with varying success. Cidofovir, a nucleotide analogue that inhibits viral DNA polymerase, is the most commonly used and has shown efficacy in hematopoietic stem cell transplant patients, though its use is limited by nephrotoxicity (Figure 9) [285–287]. Following intracellular phosphorylation to its active diphosphate form, cidofovir competes with natural deoxycytidine triphosphate during viral DNA synthesis, resulting in premature termination or marked slowing of genome elongation [288]. Current efforts to improve cidofovir-based therapies focus on reducing renal accumulation through targeted prodrug design while maintaining high intracellular concentrations within infected tissues. Ganciclovir is a guanosine nucleoside analog that inhibits adenoviral DNA polymerase, disrupting viral DNA synthesis and preventing genome replication [289]. Its antiviral activity likewise depends on intracellular conversion to the active triphosphate metabolite, allowing competitive inhibition of viral DNA polymerase during genome replication. It has also been used off-label, but its effectiveness against AdVs is less established (Figure 9) [289]. Brincidofovir, a lipid-conjugated prodrug of cidofovir that is more efficiently taken up by cells and then converted to cidofovir intracellularly, showed preclinical activity (Figure 9) [290,291]. Lipid conjugation substantially improves oral bioavailability and cellular uptake while reducing the renal toxicity associated with cidofovir [292]. Continued optimization of lipid-conjugated nucleotide analogs is directed toward improving intracellular drug delivery and limiting dose-limiting gastrointestinal toxicity.

Investigational agents like nelfinavir, which suppresses adenoviral propagation by inhibiting the lytic cell-free transmission of virions and limiting viral spread between host cells, have demonstrated *in vitro* activity (Figure 9) [293]. By limiting extracellular dissemination rather than directly inhibiting viral genome replication, nelfinavir may complement polymerase inhibitors in combination antiviral strategies.

Efforts to develop therapeutics focus on both viral and host factors critical for replication, including viral proteins like E1A and E2A, though no therapies targeting these proteins have reached clinical use. Because E1A functions as a master transcriptional

regulator that initiates viral gene expression and E2A is essential for viral DNA replication, inhibition of these early proteins could suppress multiple downstream stages of the adenoviral life cycle. Adenoviruses exploit host pathways, including HSP90 for protein maturation, mTOR for protein synthesis, and PTKs for infection [294–296]. These factors are also promising antiviral targets, as inhibitors (e.g., 17-AAG, mTOR, and PTK inhibitors) reduce replication in vitro [297]. Host-directed therapies may provide a higher genetic barrier to resistance than direct-acting antivirals because they target conserved cellular pathways rather than rapidly evolving viral proteins. Current optimization efforts are focused on selectively disrupting host factors that are preferentially utilized during adenoviral infection while minimizing toxicity associated with inhibition of essential cellular signaling pathways.




Figure 9. ADVs viral targets and mechanisms of antiviral inhibition. Cidofovir and ganciclovir act as nucleoside analogs that inhibit DNA polymerase through competitive incorporation and chain termination. Brincidofovir inhibits viral DNA polymerase by acting as a lipid-conjugated nucleotide analog that disrupts viral DNA synthesis, while nelfinavir indirectly impairs DNA polymerase-dependent replication by inhibiting viral protein processing and reducing the formation of functional replication complexes. Created in BioRender. Samrat, S. (2026) <https://BioRender.com/6y0pr0c> (DNA Polymerase).

Though antiviral agents approved for clinical use to treat adenoviruses are lacking, the integration of high-throughput screening, rational drug design, and artificial intelligence-based approaches is already accelerating adenovirus antiviral discovery by enabling the rapid identification and optimization of compounds targeting both viral proteins and host-dependency factors. Furthermore, advances in structural biology, including cryo-electron microscopy and high-resolution protein modeling, are improving the characterization of adenoviral capsid proteins and virus–host interactions, facilitating the development of more selective and effective antiviral candidates for potential clinical use [298].

Table 9. Outlines of key adenovirus (AdV) antiviral targets by comparing sequence conservation, functional constraints, resistance rates, and broad-spectrum coverage potential. It shows that highly conserved, replication-essential components such as DNA polymerase and structural capsid proteins provide the strongest therapeutic targets, while variable surface and regulatory proteins like fiber and early accessory factors exhibit higher resistance and limited cross-serotype coverage.

Viral Target	Sequence Conservation	Functional Constraint	Resistance Rate	Broad-Spectrum/Strain Coverage Potential	References
DNA polymerase	Very High	Essential for viral genome replication	Low	High (conserved across AdV serotypes)	[299,300]
Fusion/capsid proteins (e.g., penton, hexon)	High	Structural integrity is critical for viral assembly and infection	Low–Moderate	Moderate–High (structurally conserved across serotypes)	[301,302]
Fiber protein	Low–Moderate	Mediates attachment to host CAR receptor; surface-exposed	Moderate–High	Low–Moderate (variable among serotypes)	[303]
Early regulatory proteins (E1A, E2A)	Low	Modulate host machinery; not strictly essential for replication in all contexts	High	Low	[304]
Accessory Proteins	Low–Moderate	Facilitate viral replication but not strictly required	High	Low	[299]

4. Challenges and Future Directions

Despite substantial advances in target-based antiviral development, significant therapeutic gaps remain across human respiratory viruses. While approved antivirals are available for SARS-CoV-2, influenza virus, and RSV, effective therapies remain unavailable for seasonal human coronaviruses, rhinoviruses, human metapneumovirus, parainfluenza viruses, adenoviruses, measles, and rubella. Viral diversity, rapid mutation, and the emergence of antiviral resistance continue to limit the durability of many existing therapeutics, particularly those directed against highly variable surface glycoproteins. Future antiviral development should therefore increasingly prioritize highly conserved viral proteins, including RNA-dependent RNA polymerases, viral proteases, and fusion proteins, whose essential functions constrain sequence variation and make them attractive targets for broad-spectrum antiviral agents. Such therapies could provide activity against multiple viral species while strengthening preparedness for newly emerging respiratory pathogens.

Combination antiviral therapy represents another promising strategy for improving clinical outcomes and limiting antiviral resistance. Similar to treatment paradigms established for HIV and hepatitis C virus, combining agents that target distinct stages of the viral life cycle, such as entry, polyprotein processing, and genome replication, may produce synergistic antiviral activity while reducing the likelihood that resistance-conferring mutations arise against any single therapeutic target. Pairing direct-acting antivirals with host-targeted therapies may further increase the genetic barrier to resistance by simultaneously inhibiting viral proteins and host pathways required for replication. Although combination regimens have demonstrated clinical benefit during the COVID-19 pandemic, their application to other respiratory viruses remains largely unexplored and represents an important area for future investigation.

Recent advances in structural biology and artificial intelligence (AI) are also transforming antiviral drug discovery. High-resolution cryo-electron microscopy and X-ray crystallography have enabled atomic-level characterization of viral proteins, facilitating rational inhibitor design against conserved active sites. Complementing these experimental approaches, AI-driven protein structure prediction, virtual screening, molecular dynamics simulations, and machine learning algorithms are accelerating target identification, lead optimization, and prediction of resistance-associated mutations. In parallel, AI-assisted drug repurposing has expanded opportunities to rapidly identify existing therapeutics with antiviral activity, reducing both development time and cost. Continued integration of computational approaches with structural biology and experimental virology is expected to accelerate the development of next-generation antiviral therapeutics with improved potency, broader spectrum of activity, and greater resilience against viral evolution. Collectively, the studies highlighted in this review demonstrate that understanding conserved viral targets and their structural and functional properties provides the foundation for rational antiviral design, offering a framework for the development of more effective therapies against both endemic and emerging respiratory viruses.

Author Contributions: Conceptualization, S.K.S., G.S. and H.L.; methodology, S.K.S., G.S. and R.Z.; validation, S.K.S., G.S. and R.Z.; formal analysis, S.K.S., G.S. and H.L.; investigation, S.K.S., G.S. and R.Z.; resources, Z.L. and H.L.; data curation, S.K.S. and G.S.; writing—original draft preparation, S.K.S. and G.S.; writing—review and editing, S.K.S., G.S., R.Z. and H.L.; visualization, S.K.S. and H.L.; supervision, H.L.; project administration, Z.L. and H.L.; funding acquisition, H.L. All authors have read and agreed to the published version of the manuscript.

Funding: The work is supported by the University of Arizona College of Pharmacy faculty startup fund and by the R. Ken and Donna Coit Endowed Chair fund in Drug Discovery, and partially by NIH grants AI177149 and AI175435 to H.L.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments: GPT-5.6 was used only for minor grammar checks. We also used Chem draw to remake the chemical structure and pymol to recreated cyrtsal scrtutres. The authors have reviewed and edited the output and take full responsibility for the content of this publication.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Li, M.; Liu, M.; Liu, J. Trends in the Mortality, Deaths, and Aetiologies of Lower Respiratory Infections Among 204 Countries from 1991 to 2021: An Updated Systematic Study. *Viruses* **2025**, *17*, 892. [CrossRef] [PubMed]
2. Available online: [https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-\(rsv\)](https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-(rsv)) (accessed on 12 August 2026).
3. Centers for Disease Control and Prevention. *CDC Yellow Book: Health Information for International Travel*; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2026; Volume 2026. Available online: <https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/influenza.html> (accessed on 12 August 2026).
4. Taubenberger, J.K.; Morens, D.M. The 1918 Influenza Pandemic and Its Legacy. *Cold Spring Harb. Perspect. Med.* **2020**, *10*, a038695. [CrossRef] [PubMed]
5. World Health Organization. *WHO Data*; World Health Organization: Geneva, Switzerland, 2024; Volume 2026.
6. Falsey, A.R.; Branche, A.R. *International Encyclopedia of Public Health*; Elsevier: Amsterdam, The Netherlands, 2017; pp. 363–369.
7. Lee, E.; Gern, J.E. Clinical Significance of Rhinoviruses and Progress Toward Vaccination. *Allergy Asthma Immunol. Res.* **2025**, *17*, 414–432. [CrossRef] [PubMed]

8. Maggi, S.; Launay, O.; Dawson, R. Respiratory Virus Vaccines: Pathways to Recommendations and Enhanced Coverage for At-Risk Populations. *Infect. Dis. Ther.* **2025**, *14*, 99–114. [\[CrossRef\]](#) [\[PubMed\]](#)
9. Livieratos, A.; Schiro, L.E.; Gogos, C.; Akinosoglou, K. Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2. *Vaccines* **2024**, *12*, 1444. [\[CrossRef\]](#) [\[PubMed\]](#)
10. Luring, A.S.; Tenforde, M.W.; Chappell, J.D.; Gaglani, M.; Ginde, A.A.; McNeal, T.; Ghamande, S.; Douin, D.J.; Talbot, H.K.; Casey, J.D.; et al. Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. *BMJ* **2022**, *376*, e069761. [\[CrossRef\]](#) [\[PubMed\]](#)
11. Alvarez de Toledo, M.; Taveras, J.I.; Ramilo, O.; Mejias, A. Antiviral therapies for respiratory syncytial virus infection: Current expectations. *Curr. Opin. Infect. Dis.* **2026**, *39*, 153–159. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Tejada, S.; Martinez-Reviejo, R.; Karakoc, H.N.; Peña-López, Y.; Manuel, O.; Rello, J. Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis. *Adv. Ther.* **2022**, *39*, 4037–4051. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Available online: <https://www.cdc.gov/rhinoviruses/about/index.html> (accessed on 12 August 2026).
14. McNicholl, I.R.; McNicholl, J.J. Neuraminidase inhibitors: Zanamivir and oseltamivir. *Ann. Pharmacother.* **2001**, *35*, 57–70. [\[CrossRef\]](#) [\[PubMed\]](#)
15. Webster, D.; Li, Y.; Bastien, N.; Garceau, R.; Hatchette, T.F. Oseltamivir-resistant pandemic H1N1 influenza. *Can. Med. Assoc. J.* **2011**, *183*, E420–E422. [\[CrossRef\]](#) [\[PubMed\]](#)
16. Ryoo, S.; Choi, M.; Yu, S.Y.; Yoon, Y.K.; Huh, K.; Joo, E.J. The effects of remdesivir on mortality and the requirement for mechanical ventilation in patients with COVID-19: A systematic review stratified by disease severity. *Korean J. Intern. Med.* **2024**, *39*, 160–171. [\[CrossRef\]](#) [\[PubMed\]](#)
17. Bansal, V.; Mahapure, K.S.; Bhurwal, A.; Gupta, I.; Hassanain, S.; Makadia, J.; Madas, N.; Armaly, P.; Singh, R.; Mehra, I.; et al. Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis. *Front. Med.* **2020**, *7*, 606429. [\[CrossRef\]](#) [\[PubMed\]](#)
18. Masyeni, S.; Iqhrammullah, M.; Frediansyah, A.; Nainu, F.; Tallei, T.; Emran, T.B.; Ophinni, Y.; Dhama, K.; Harapan, H. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review. *J. Med. Virol.* **2022**, *94*, 3006–3016. [\[CrossRef\]](#) [\[PubMed\]](#)
19. Sanderson, T.; Hisner, R.; Donovan-Banfield, I.; Hartman, H.; Løchen, A.; Peacock, T.P.; Ruis, C. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. *Nature* **2023**, *623*, 594–600. [\[CrossRef\]](#) [\[PubMed\]](#)
20. Maideen, N.M.P.; Kandasamy, K.; Balasubramanian, R. Pharmacokinetic Interactions of Paxlovid Involving CYP3A Enzymes and P-gp Transporter: An Overview of Clinical Data. *Curr. Drug Metab.* **2024**, *25*, 639–652. [\[CrossRef\]](#) [\[PubMed\]](#)
21. Perelson, A.S.; Ribeiro, R.M.; Phan, T. An explanation for SARS-CoV-2 rebound after Paxlovid treatment. *medRxiv* **2023**. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Knowles, S.R.; Phillips, E.J.; Dresser, L.; Matukas, L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. *Clin. Infect. Dis.* **2003**, *37*, 1139–1142. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Pleschka, S. Special Issue “Host Targeted Therapeutics Against Virus Infections”. *Viruses* **2024**, *16*, 1825. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Alanazi, A.; Ibrahim, M.N.; El Azab, E.F.; Elithy, M.A. Host Cell Virus Interactions: Molecular Mechanisms, Immune Modulation, Viral Pathogenesis, and Emerging Therapeutic Targets. *Viruses* **2026**, *18*, 125. [\[CrossRef\]](#) [\[PubMed\]](#)
25. Dai, J.; Jiang, X.; da Silva-Júnior, E.F.; Du, S.; Liu, X.; Zhan, P. Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities. *Drug Discov. Today* **2024**, *29*, 104074. [\[CrossRef\]](#) [\[PubMed\]](#)
26. Owen, D.R.; Allerton, C.M.N.; Anderson, A.S.; Aschenbrenner, L.; Avery, M.; Berritt, S.; Boras, B.; Cardin, R.D.; Carlo, A.; Coffman, K.J.; et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. *Science* **2021**, *374*, 1586–1593. [\[CrossRef\]](#) [\[PubMed\]](#)
27. Greasley, S.E.; Noell, S.; Plotnikova, O.; Ferre, R.; Liu, W.; Bolanos, B.; Fennell, K.; Nicki, J.; Craig, T.; Zhu, Y.; et al. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. *J. Biol. Chem.* **2022**, *298*, 101972. [\[CrossRef\]](#) [\[PubMed\]](#)
28. Eastman, R.T.; Roth, J.S.; Brimacombe, K.R.; Simeonov, A.; Shen, M.; Patnaik, S.; Hall, M.D. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. *ACS Cent. Sci.* **2020**, *6*, 672–683. [\[CrossRef\]](#) [\[PubMed\]](#)
29. Centers for Disease Control and Prevention. *CDC Yellow Book: Health Information for International Travel*; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2025.
30. Centers for Disease Control and Prevention. *Influenza (Flu)*; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2026; Volume 2026.
31. Fukao, K.; Ando, Y.; Noshi, T.; Kitano, M.; Noda, T.; Kawai, M.; Yoshida, R.; Sato, A.; Shishido, T.; Naito, A. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. *PLoS ONE* **2019**, *14*, e0217307. [\[CrossRef\]](#) [\[PubMed\]](#)

32. Dufrasne, F. Baloxavir Marboxil: An Original New Drug against Influenza. *Pharmaceuticals* **2021**, *15*, 28. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Yang, G.; Jiang, G.; Jiang, J.; Li, Y. Advances in development of antiviral strategies against respiratory syncytial virus. *Acta Pharm. Sin. B* **2025**, *15*, 1752–1772. [\[CrossRef\]](#) [\[PubMed\]](#)
34. Fehr, A.R.; Perlman, S. Coronaviruses: An overview of their replication and pathogenesis. *Methods Mol. Biol.* **2015**, *1282*, 1–23. [\[CrossRef\]](#) [\[PubMed\]](#)
35. Hartenian, E.; Nandakumar, D.; Lari, A.; Ly, M.; Tucker, J.M.; Glaunsinger, B.A. The molecular virology of coronaviruses. *J. Biol. Chem.* **2020**, *295*, 12910–12934. [\[CrossRef\]](#) [\[PubMed\]](#)
36. Jin, Z.; Wang, H.; Duan, Y.; Yang, H. The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2. *Biochem. Biophys. Res. Commun.* **2021**, *538*, 63–71. [\[CrossRef\]](#) [\[PubMed\]](#)
37. Melo-Filho, C.C.; Bobrowski, T.; Martin, H.J.; Sessions, Z.; Popov, K.I.; Moorman, N.J.; Baric, R.S.; Muratov, E.N.; Tropsha, A. Conserved coronavirus proteins as targets of broad-spectrum antivirals. *Antivir. Res.* **2022**, *204*, 105360. [\[CrossRef\]](#) [\[PubMed\]](#)
38. Zumla, A.; Chan, J.F.; Azhar, E.I.; Hui, D.S.; Yuen, K.Y. Coronaviruses—Drug discovery and therapeutic options. *Nat. Rev. Drug Discov.* **2016**, *15*, 327–347. [\[CrossRef\]](#) [\[PubMed\]](#)
39. Ataya, F.; Alamro, A.; Alghamdi, A.; Fouad, D. SARS-CoV-2 spike mutations alter structure and energetics to modulate ACE2 binding immune evasion and viral adaptation. *Sci. Rep.* **2025**, *15*, 37546. [\[CrossRef\]](#) [\[PubMed\]](#)
40. López-Cortés, G.I.; Palacios-Pérez, M.; Veledíaz, H.F.; Hernández-Aguilar, M.; López-Hernández, G.R.; Zamudio, G.S.; José, M.V. The Spike Protein of SARS-CoV-2 Is Adapting Because of Selective Pressures. *Vaccines* **2022**, *10*, 864. [\[CrossRef\]](#) [\[PubMed\]](#)
41. Tarannum, H.; Rashmi, K.M.; Nandi, S. Exploring the SARS-CoV-2 Main Protease (M(pro)) and RdRp Targets by Updating Current Structure-based Drug Design Utilizing Co-crystals to Combat COVID-19. *Curr. Drug Targets* **2022**, *23*, 802–817. [\[CrossRef\]](#) [\[PubMed\]](#)
42. de Wit, E.; Feldmann, F.; Cronin, J.; Jordan, R.; Okumura, A.; Thomas, T.; Scott, D.; Cihlar, T.; Feldmann, H. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 6771–6776. [\[CrossRef\]](#) [\[PubMed\]](#)
43. Lyles, K.V.; Stone, S.; Singh, P.; Patterson, L.D.; Natekar, J.; Pathak, H.; Varshnaya, R.K.; Elsharkawy, A.; Liu, D.; Bansal, S.; et al. Entry Inhibitors of SARS-CoV-2 Targeting the Transmembrane Domain of the Spike Protein. *Viruses* **2025**, *17*, 989. [\[CrossRef\]](#) [\[PubMed\]](#)
44. Qin, H.; Ni, H.; Liu, Y.; Yuan, Y.; Xi, T.; Li, X.; Zheng, L. RNA-binding proteins in tumor progression. *J. Hematol. Oncol.* **2020**, *13*, 90. [\[CrossRef\]](#) [\[PubMed\]](#)
45. Venkataraman, S.; Prasad, B.; Selvarajan, R. RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution. *Viruses* **2018**, *10*, 76. [\[CrossRef\]](#) [\[PubMed\]](#)
46. Riley, T.P.; Chou, H.T.; Hu, R.; Bzymek, K.P.; Correia, A.R.; Partin, A.C.; Li, D.; Gong, D.; Wang, Z.; Yu, X.; et al. Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein Through Structure-Guided Design. *Front. Immunol.* **2021**, *12*, 660198. [\[CrossRef\]](#) [\[PubMed\]](#)
47. Zan, F.; Zhou, Y.; Chen, T.; Chen, Y.; Mu, Z.; Qian, Z.; Ou, X. Stabilization of the Metastable Pre-Fusion Conformation of the SARS-CoV-2 Spike Glycoprotein through N-Linked Glycosylation of the S2 Subunit. *Viruses* **2024**, *16*, 223. [\[CrossRef\]](#) [\[PubMed\]](#)
48. Huynh, T.; Cornell, W.; Luan, B. In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease. *Front. Chem.* **2020**, *8*, 624163. [\[CrossRef\]](#) [\[PubMed\]](#)
49. Portales, A.E.; Mustafá, E.R.; McCarthy, C.I.; Cornejo, M.P.; Couto, P.M.; Gironacci, M.M.; Caramelo, J.J.; Perelló, M.; Raingo, J. ACE2 internalization induced by a SARS-CoV-2 recombinant protein is modulated by angiotensin II type 1 and bradykinin 2 receptors. *Life Sci.* **2022**, *293*, 120284. [\[CrossRef\]](#) [\[PubMed\]](#)
50. Liu, D.X.; Liang, J.Q.; Fung, T.S. Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). *Encycl. Virol.* **2021**, *2*, 428–440. [\[CrossRef\]](#)
51. Siragam, V.; Maltseva, M.; Castonguay, N.; Galipeau, Y.; Srinivasan, M.M.; Soto, J.H.; Dankar, S.; Langlois, M.A. Seasonal human coronaviruses OC43, 229E, and NL63 induce cell surface modulation of entry receptors and display host cell-specific viral replication kinetics. *Microbiol. Spectr.* **2024**, *12*, e0422023. [\[CrossRef\]](#) [\[PubMed\]](#)
52. Yang, K.; Wang, C.; White, K.I.; Pfuetzner, R.A.; Esquivies, L.; Brunger, A.T. Structural conservation among variants of the SARS-CoV-2 spike postfusion bundle. *Proc. Natl. Acad. Sci. USA* **2022**, *119*, e2119467119. [\[CrossRef\]](#) [\[PubMed\]](#)
53. Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **2020**, *367*, 1260–1263. [\[CrossRef\]](#) [\[PubMed\]](#)
54. Datta, P.K.; Liu, F.; Fischer, T.; Rappaport, J.; Qin, X. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. *Theranostics* **2020**, *10*, 7448–7464. [\[CrossRef\]](#) [\[PubMed\]](#)
55. Li, Y.; Zhou, W.; Yang, L.; You, R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. *Pharmacol. Res.* **2020**, *157*, 104833. [\[CrossRef\]](#) [\[PubMed\]](#)

56. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **2020**, *181*, 271–280.e278. [[CrossRef](#)] [[PubMed](#)]
57. Shi, W.; Jonaid, G.M.; Kibria, M.G.; Allen, J.; Peng, H.; Rits-Volloch, S.; Zhu, H.; Wang, S.; Walsh, R.M.; Lu, J.; et al. Effect of the S2' site cleavage on SARS-CoV-2 spike. *Nat. Commun.* **2025**, *16*, 11675. [[CrossRef](#)] [[PubMed](#)]
58. Hoffmann, M.; Kleine-Weber, H.; Pöhlmann, S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol. Cell* **2020**, *78*, 779–784.e775. [[CrossRef](#)] [[PubMed](#)]
59. Ghimire, D.; Han, Y.; Lu, M. Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. *Viruses* **2022**, *14*, 1255. [[CrossRef](#)] [[PubMed](#)]
60. Fantini, J.; Yahi, N.; Azzaz, F.; Chahinian, H. Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating COVID-19 outbreaks. *J. Infect.* **2021**, *83*, 197–206. [[CrossRef](#)] [[PubMed](#)]
61. Soares, V.C.; Moreira, I.B.G.; Dias, S.S.G. SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations. *Viruses* **2025**, *17*, 1064. [[CrossRef](#)] [[PubMed](#)]
62. Tumskiy, R.S.; Tumskaya, A.V.; Klochkova, I.N.; Richardson, R.J. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations. *Comput. Biol. Med.* **2023**, *153*, 106449. [[CrossRef](#)] [[PubMed](#)]
63. Gordon, C.J.; Tchesnokov, E.P.; Woolner, E.; Perry, J.K.; Feng, J.Y.; Porter, D.P.; Götte, M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. *J. Biol. Chem.* **2020**, *295*, 6785–6797. [[CrossRef](#)] [[PubMed](#)]
64. Kabinger, F.; Stiller, C.; Schmitzová, J.; Dienemann, C.; Kokic, G.; Hillen, H.S.; Höbartner, C.; Cramer, P. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. *Nat. Struct. Mol. Biol.* **2021**, *28*, 740–746. [[CrossRef](#)] [[PubMed](#)]
65. Cox, R.M.; Wolf, J.D.; Lieber, C.M.; Sourimant, J.; Lin, M.J.; Babusis, D.; DuPont, V.; Chan, J.; Barrett, K.T.; Lye, D.; et al. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. *Nat. Commun.* **2021**, *12*, 6415. [[CrossRef](#)] [[PubMed](#)]
66. Yang, Y.; Li, Y.; Becker, S.T.; Khan, A.; Luo, G.; Liu, B.; Liu, C. Molecular basis of SARS-CoV-2 proofreading enzyme-mediated resistance to remdesivir. *Proc. Natl. Acad. Sci. USA* **2025**, *122*, e2519755122. [[CrossRef](#)] [[PubMed](#)]
67. Noske, G.D.; de Souza Silva, E.; de Godoy, M.O.; Dolci, I.; Fernandes, R.S.; Guido, R.V.C.; Sjö, P.; Oliva, G.; Godoy, A.S. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease. *J. Biol. Chem.* **2023**, *299*, 103004. [[CrossRef](#)] [[PubMed](#)]
68. Gammeltoft, K.A.; Zhou, Y.; Ryberg, L.A.; Pham, L.V.; Binderup, A.; Hernandez, C.R.D.; Offersgaard, A.; Fahnøe, U.; Peters, G.H.J.; Ramirez, S.; et al. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir. *Viruses* **2023**, *15*, 1970. [[CrossRef](#)] [[PubMed](#)]
69. Mukae, H.; Yotsuyanagi, H.; Ohmagari, N.; Doi, Y.; Yamato, M.; Imamura, T.; Sakaguchi, H.; Sanaki, T.; Sonoyama, T.; Tsuge, Y.; et al. Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: A narrative literature review. *Ther. Adv. Infect. Dis.* **2025**, *12*, 20499361251321724. [[CrossRef](#)] [[PubMed](#)]
70. Huang, C.; Shuai, H.; Qiao, J.; Hou, Y.; Zeng, R.; Xia, A.; Xie, L.; Fang, Z.; Li, Y.; Yoon, C.; et al. A new generation M(pro) inhibitor with potent activity against SARS-CoV-2 Omicron variants. *Signal Transduct. Target. Ther.* **2023**, *8*, 128. [[CrossRef](#)] [[PubMed](#)]
71. McCarthy, M.W. Simnoretelvir as a potential treatment for COVID-19. *Expert. Opin. Pharmacother.* **2024**, *25*, 233–237. [[CrossRef](#)] [[PubMed](#)]
72. Zhan, Y.; Lin, Z.; Liang, J.; Sun, R.; Li, Y.; Lin, B.; Ge, F.; Lin, L.; Lu, H.; Su, L.; et al. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: A multicentre randomised, double-blind, placebo-controlled phase 3 trial. *EClinicalMedicine* **2024**, *67*, 102359. [[CrossRef](#)] [[PubMed](#)]
73. Zhao, W.; Lupala, C.S.; Hou, S.; Yang, S.; Yan, Z.; Liao, S.; Li, X.; Li, N. Assessing the inhibition efficacy of clinical drugs against the main proteases of SARS-CoV-2 variants and other coronaviruses. *Quant. Biol.* **2024**, *12*, 324–328. [[CrossRef](#)] [[PubMed](#)]
74. Zhu, K.W. Deuremidivir and Simnoretelvir-Ritonavir for the Treatment of COVID-19. *ACS Pharmacol. Transl. Sci.* **2023**, *6*, 1306–1309. [[CrossRef](#)] [[PubMed](#)]
75. Ratia, K.; Pegan, S.; Takayama, J.; Sleeman, K.; Coughlin, M.; Baliji, S.; Chaudhuri, R.; Fu, W.; Prabhakar, B.S.; Johnson, M.E.; et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 16119–16124. [[CrossRef](#)] [[PubMed](#)]
76. Wu, X.; Devine, S.M.; Go, M.; Nguyen, J.V.; Lu, B.G.C.; Loi, K.; Kuchel, N.W.; Lowes, K.N.; Mitchell, J.P.; Lessene, G.; et al. Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity. *PLoS Pathog.* **2025**, *21*, e1013468. [[CrossRef](#)] [[PubMed](#)]
77. Cao, D.; Duan, L.; Huang, B.; Xiong, Y.; Zhang, G.; Huang, H. The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING. *Sci. Signal.* **2023**, *16*, eadd0082. [[CrossRef](#)] [[PubMed](#)]

78. Miguez-Rey, E.; Choi, D.; Kim, S.; Yoon, S.; Săndulescu, O. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. *Expert. Opin. Investig. Drugs* **2022**, *31*, 41–58. [\[CrossRef\]](#) [\[PubMed\]](#)
79. Pantaleo, G.; Correia, B.; Fenwick, C.; Joo, V.S.; Perez, L. Antibodies to combat viral infections: Development strategies and progress. *Nat. Rev. Drug Discov.* **2022**, *21*, 676–696. [\[CrossRef\]](#) [\[PubMed\]](#)
80. Zitek, T.; Pardin, B.; Farcy, D.A. Banning Monoclonal Antibody Therapies for COVID-19 Using In Vitro Data. *South. Med. J.* **2023**, *116*, 245. [\[CrossRef\]](#) [\[PubMed\]](#)
81. Available online: <https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs> (accessed on 12 August 2026).
82. Nasonov, E.; Samsonov, M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. *Biomed. Pharmacother.* **2020**, *131*, 110698. [\[CrossRef\]](#) [\[PubMed\]](#)
83. Obeagu, E.I. Immunomodulatory strategies for managing cytokine storms in chronic COVID: Mechanisms, therapeutic targets, and clinical advances. *Ann. Med. Surg.* **2026**, *88*, 653–659. [\[CrossRef\]](#) [\[PubMed\]](#)
84. Mohseni Afshar, Z.; Tavakoli Pirzaman, A.; Hosseinzadeh, R.; Babazadeh, A.; Taghizadeh Moghadam, M.A.; Miri, S.R.; Sio, T.T.; Sullman, M.J.M.; Barary, M.; Ebrahimpour, S. Anticoagulant therapy in COVID-19: A narrative review. *Clin. Transl. Sci.* **2023**, *16*, 1510–1525. [\[CrossRef\]](#) [\[PubMed\]](#)
85. Schreiber, A.; Ludwig, S. Host-targeted antivirals against SARS-CoV-2 in clinical development—Prospect or disappointment? *Antivir. Res.* **2025**, *235*, 106101. [\[CrossRef\]](#) [\[PubMed\]](#)
86. He, Y.; Zhou, J.; Gao, H.; Liu, C.; Zhan, P.; Liu, X. Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses. *Eur. J. Med. Chem.* **2024**, *265*, 116069. [\[CrossRef\]](#) [\[PubMed\]](#)
87. Aw, D.Z.H.; Zhang, D.X.; Vignuzzi, M. Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals. *NPJ Antimicrob. Resist.* **2025**, *3*, 54. [\[CrossRef\]](#) [\[PubMed\]](#)
88. Wu, J.; Chen, Z.; Han, X.; Chen, Q.; Wang, Y.; Feng, T. SARS-CoV-2 RNA-dependent RNA polymerase as a target for high-throughput drug screening. *Future Virol.* **2022**, *18*, 51–62. [\[CrossRef\]](#) [\[PubMed\]](#)
89. Lee, J.T.; Yang, Q.; Gribenko, A.; Perrin, B.S., Jr.; Zhu, Y.; Cardin, R.; Liberator, P.A.; Anderson, A.S.; Hao, L. Genetic Surveillance of SARS-CoV-2 M(pro) Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid. *mBio* **2022**, *13*, e0086922. [\[CrossRef\]](#) [\[PubMed\]](#)
90. Ullrich, S.; Nitsche, C. The SARS-CoV-2 main protease as drug target. *Bioorg. Med. Chem. Lett.* **2020**, *30*, 127377. [\[CrossRef\]](#) [\[PubMed\]](#)
91. Shin, D.; Mukherjee, R.; Grewe, D.; Bojkova, D.; Baek, K.; Bhattacharya, A.; Schulz, L.; Widera, M.; Mehdipour, A.R.; Tascher, G.; et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. *Nature* **2020**, *587*, 657–662. [\[CrossRef\]](#) [\[PubMed\]](#)
92. Walls, A.C.; Park, Y.J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Veesler, D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **2020**, *181*, 281–292.e286. [\[CrossRef\]](#) [\[PubMed\]](#)
93. Fang, P.; Fang, L.; Zhang, H.; Xia, S.; Xiao, S. Functions of Coronavirus Accessory Proteins: Overview of the State of the Art. *Viruses* **2021**, *13*, 1139. [\[CrossRef\]](#) [\[PubMed\]](#)
94. Piasecka, J.; Jarmolowicz, A.; Kierzek, E. Organization of the Influenza A Virus Genomic RNA in the Viral Replication Cycle—Structure, Interactions, and Implications for the Emergence of New Strains. *Pathogens* **2020**, *9*, 951. [\[CrossRef\]](#) [\[PubMed\]](#)
95. Stevaert, A.; Naesens, L. The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design. *Med. Res. Rev.* **2016**, *36*, 1127–1173. [\[CrossRef\]](#) [\[PubMed\]](#)
96. Wu, N.C.; Wilson, I.A. A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus. *J. Mol. Biol.* **2017**, *429*, 2694–2709. [\[CrossRef\]](#) [\[PubMed\]](#)
97. Wu, N.C.; Wilson, I.A. Influenza Hemagglutinin Structures and Antibody Recognition. *Cold Spring Harb. Perspect. Med.* **2020**, *10*, a038778. [\[CrossRef\]](#) [\[PubMed\]](#)
98. Zhang, J.; Hu, Y.; Musharrafieh, R.; Yin, H.; Wang, J. Focusing on the Influenza Virus Polymerase Complex: Recent Progress in Drug Discovery and Assay Development. *Curr. Med. Chem.* **2019**, *26*, 2243–2263. [\[CrossRef\]](#) [\[PubMed\]](#)
99. Garcia, N.K.; Kephart, S.M.; Benhaim, M.A.; Matsui, T.; Mileant, A.; Guttman, M.; Lee, K.K. Structural dynamics reveal subtype-specific activation and inhibition of influenza virus hemagglutinin. *J. Biol. Chem.* **2023**, *299*, 104765. [\[CrossRef\]](#) [\[PubMed\]](#)
100. Shtyrya, Y.A.; Mochalova, L.V.; Bovin, N.V. Influenza virus neuraminidase: Structure and function. *Acta Naturae* **2009**, *1*, 26–32. [\[CrossRef\]](#)
101. Fan, H.; Walker, A.P.; Carrique, L.; Keown, J.R.; Serna Martin, I.; Karia, D.; Sharps, J.; Hengrung, N.; Pardon, E.; Steyaert, J.; et al. Structures of influenza A virus RNA polymerase offer insight into viral genome replication. *Nature* **2019**, *573*, 287–290. [\[CrossRef\]](#) [\[PubMed\]](#)
102. Michalski, M.; Setny, P. Molecular Mechanisms behind Conformational Transitions of the Influenza Virus Hemagglutinin Membrane Anchor. *J. Phys. Chem. B* **2023**, *127*, 9450–9460. [\[CrossRef\]](#) [\[PubMed\]](#)

103. Ellis, D.; Lederhofer, J.; Acton, O.J.; Tsybovsky, Y.; Kephart, S.; Yap, C.; Gillespie, R.A.; Creanga, A.; Olshefsky, A.; Stephens, T.; et al. Structure-based design of stabilized recombinant influenza neuraminidase tetramers. *Nat. Commun.* **2022**, *13*, 1825. [[CrossRef](#)] [[PubMed](#)]
104. Luo, M. Influenza virus entry. *Adv. Exp. Med. Biol.* **2012**, *726*, 201–221. [[CrossRef](#)] [[PubMed](#)]
105. Byrd-Leotis, L.; Cummings, R.D.; Steinhauer, D.A. The Interplay between the Host Receptor and Influenza Virus Hemagglutinin and Neuraminidase. *Int. J. Mol. Sci.* **2017**, *18*, 1541. [[CrossRef](#)] [[PubMed](#)]
106. Todd, B.; Tchesnokov, E.P.; Götte, M. The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor. *J. Biol. Chem.* **2021**, *296*, 100486. [[CrossRef](#)] [[PubMed](#)]
107. Baranovich, T.; Wong, S.S.; Armstrong, J.; Marjuki, H.; Webby, R.J.; Webster, R.G.; Govorkova, E.A. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. *J. Virol.* **2013**, *87*, 3741–3751. [[CrossRef](#)] [[PubMed](#)]
108. Checkmahomed, L.; M’Hamdi, Z.; Carbonneau, J.; Venable, M.C.; Baz, M.; Abed, Y.; Boivin, G. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains. *J. Infect. Dis.* **2020**, *221*, 63–70. [[CrossRef](#)] [[PubMed](#)]
109. Kiso, M.; Lopes, T.J.S.; Yamayoshi, S.; Ito, M.; Yamashita, M.; Nakajima, N.; Hasegawa, H.; Neumann, G.; Kawaoka, Y. Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus. *J. Infect. Dis.* **2018**, *217*, 887–896. [[CrossRef](#)] [[PubMed](#)]
110. Alame, M.M.; Massaad, E.; Zaraket, H. Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections. *Front. Microbiol.* **2016**, *7*, 450. [[CrossRef](#)] [[PubMed](#)]
111. McLaughlin, M.M.; Skoglund, E.W.; Ison, M.G. Peramivir: An intravenous neuraminidase inhibitor. *Expert Opin. Pharmacother.* **2015**, *16*, 1889–1900. [[CrossRef](#)] [[PubMed](#)]
112. Xu, J.; Luo, Q.; Huang, Y.; Li, J.; Ye, W.; Yan, R.; Zhou, X.; He, Z.; Liu, G.; Zhu, Q. Influenza neuraminidase mutations and resistance to neuraminidase inhibitors. *Emerg. Microbes Infect.* **2024**, *13*, 2429627. [[CrossRef](#)] [[PubMed](#)]
113. Scott, C.; Kankanala, J.; Foster, T.L.; Goldhill, D.H.; Bao, P.; Simmons, K.; Pinggen, M.; Bentham, M.; Atkins, E.; Loundras, E.; et al. Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. *PLoS Pathog.* **2020**, *16*, e1008716. [[CrossRef](#)] [[PubMed](#)]
114. Mahrous, N.N.; Alhumaidan, O.S.; Alkhoshaiban, A.S.; Tafish, R.T.; Al-Ghnnam, F.F.; Althubayani, M.; Al-Hubaysh, A.; Jamous, Y.F. Broadly neutralizing monoclonal antibodies against influenza A viruses: Current insights and future directions. *Front. Microbiol.* **2025**, *16*, 1738181. [[CrossRef](#)] [[PubMed](#)]
115. Beran, R.K.; Vijapurapu, A.; Nair, V.; Du Pont, V. Host-targeted antivirals as broad-spectrum inhibitors of respiratory viruses. *Curr. Opin. Virol.* **2025**, *73*, 101492. [[CrossRef](#)] [[PubMed](#)]
116. Hui, X.; Ding, S.; Gao, S.; Xu, S.; Zhao, T.; Tian, X.; Wang, H. Host-Directed Antiviral Strategies Against Influenza Viruses: Host Targets, Multi-Omics Approaches and AI-Assisted Discovery. *Vet. Sci.* **2026**, *13*, 626. [[CrossRef](#)] [[PubMed](#)]
117. Matsunaga, N. Emerging host-targeted antivirals for respiratory viruses: Antivirals targeting virus elements versus host mechanisms. *Next Res.* **2026**, *5*, 101311. [[CrossRef](#)]
118. Ghanem, A.; Mayer, D.; Chase, G.; Tegge, W.; Frank, R.; Kochs, G.; García-Sastre, A.; Schwemmler, M. Peptide-mediated interference with influenza A virus polymerase. *J. Virol.* **2007**, *81*, 7801–7804. [[CrossRef](#)] [[PubMed](#)]
119. Laborda, P.; Wang, S.Y.; Voglmeir, J. Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity. *Molecules* **2016**, *21*, 1513. [[CrossRef](#)] [[PubMed](#)]
120. Ohuchi, M.; Asaoka, N.; Sakai, T.; Ohuchi, R. Roles of neuraminidase in the initial stage of influenza virus infection. *Microbes Infect.* **2006**, *8*, 1287–1293. [[CrossRef](#)] [[PubMed](#)]
121. Shen, X.; Zhang, X.; Liu, S. Novel hemagglutinin-based influenza virus inhibitors. *J. Thorac. Dis.* **2013**, *5*, S149–S159. [[CrossRef](#)] [[PubMed](#)]
122. Kumar, G.; Saktharam, K.A. Tackling Influenza A virus by M2 ion channel blockers: Latest progress and limitations. *Eur. J. Med. Chem.* **2024**, *267*, 116172. [[CrossRef](#)] [[PubMed](#)]
123. Jalily, P.H.; Duncan, M.C.; Fedida, D.; Wang, J.; Tietjen, I. Put a cork in it: Plugging the M2 viral ion channel to sink influenza. *Antivir. Res.* **2020**, *178*, 104780. [[CrossRef](#)] [[PubMed](#)]
124. Pinto, R.M.; Lycett, S.; Gaunt, E.; Digard, P. Accessory Gene Products of Influenza A Virus. *Cold Spring Harb. Perspect. Med.* **2021**, *11*, a038380. [[CrossRef](#)] [[PubMed](#)]
125. Chamarthi, S.; Chamarthi, V.S.; Daley, S.F. Respiratory Syncytial Virus Infection in Children. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2026.
126. Bergeron, H.C.; Tripp, R.A. RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein. *Viruses* **2022**, *14*, 2396. [[CrossRef](#)] [[PubMed](#)]
127. Kaler, J.; Hussain, A.; Patel, K.; Hernandez, T.; Ray, S. Respiratory Syncytial Virus: A Comprehensive Review of Transmission, Pathophysiology, and Manifestation. *Cureus* **2023**, *15*, e36342. [[CrossRef](#)] [[PubMed](#)]

128. Zhang, L.; Peeples, M.E.; Boucher, R.C.; Collins, P.L.; Pickles, R.J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. *J. Virol.* **2002**, *76*, 5654–5666. [\[CrossRef\]](#) [\[PubMed\]](#)
129. McLellan, J.S.; Ray, W.C.; Peeples, M.E. Structure and function of respiratory syncytial virus surface glycoproteins. *Curr. Top. Microbiol. Immunol.* **2013**, *372*, 83–104. [\[CrossRef\]](#) [\[PubMed\]](#)
130. Tian, J.; Huang, K.; Krishnan, S.; Svabek, C.; Rowe, D.C.; Brewah, Y.; Sanjuan, M.; Patera, A.C.; Kolbeck, R.; Herbst, R.; et al. RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function. *J. Gen. Virol.* **2013**, *94*, 1691–1700. [\[CrossRef\]](#) [\[PubMed\]](#)
131. König, P.; Giesow, K.; Schuldt, K.; Buchholz, U.J.; Keil, G.M. A novel protein expression strategy using recombinant bovine respiratory syncytial virus (BRSV): Modifications of the peptide sequence between the two furin cleavage sites of the BRSV fusion protein yield secreted proteins, but affect processing and function of the BRSV fusion protein. *J. Gen. Virol.* **2004**, *85*, 1815–1824. [\[CrossRef\]](#) [\[PubMed\]](#)
132. Asseri, A.A. Respiratory Syncytial Virus: A Narrative Review of Updates and Recent Advances in Epidemiology, Pathogenesis, Diagnosis, Management and Prevention. *J. Clin. Med.* **2025**, *14*, 3880. [\[CrossRef\]](#) [\[PubMed\]](#)
133. Cao, D.; Gao, Y.; Liang, B. Structural Insights into the Respiratory Syncytial Virus RNA Synthesis Complexes. *Viruses* **2021**, *13*, 834. [\[CrossRef\]](#) [\[PubMed\]](#)
134. Collins, P.L.; Fearn, R.; Graham, B.S. Respiratory syncytial virus: Virology, reverse genetics, and pathogenesis of disease. *Curr. Top. Microbiol. Immunol.* **2013**, *372*, 3–38. [\[CrossRef\]](#) [\[PubMed\]](#)
135. Bakker, S.E.; Duquerroy, S.; Galloux, M.; Loney, C.; Conner, E.; Eléouët, J.F.; Rey, F.A.; Bhella, D. The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid. *J. Gen. Virol.* **2013**, *94*, 1734–1738. [\[CrossRef\]](#) [\[PubMed\]](#)
136. Neal, H.E.; Barrett, C.T.; Edmonds, K.; Moncman, C.L.; Dutch, R.E. Examination of respiratory syncytial virus fusion protein proteolytic processing and roles of the P27 domain. *J. Virol.* **2024**, *98*, e0163924. [\[CrossRef\]](#) [\[PubMed\]](#)
137. Wang, F.; Jiang, M.; Han, Z.; Xu, Y.; Sun, Y.; Zhu, R.; Chen, D.; Guo, Q.; Zhou, Y.; Yao, Y.; et al. The Cumulative Variations of Respiratory Syncytial Virus Fusion Protein (F) in Ten Consecutive Years in China. *Infect. Dis. Rep.* **2024**, *16*, 1017–1029. [\[CrossRef\]](#) [\[PubMed\]](#)
138. Anderson, J.; Do, L.A.H.; van Kasteren, P.B.; Licciardi, P.V. The role of respiratory syncytial virus G protein in immune cell infection and pathogenesis. *EBioMedicine* **2024**, *107*, 105318. [\[CrossRef\]](#) [\[PubMed\]](#)
139. Yu, D.; Zhang, C.; Qi, Y.; Liu, Z.; Yang, D.; Zhao, N.; Ke, Z.; Lu, X.; Li, Y. RSV Vaccines: Targeting Prefusion F and G Proteins from Structural Design to Clinical Application. *Vaccines* **2025**, *13*, 1133. [\[CrossRef\]](#) [\[PubMed\]](#)
140. Tang, A.; Chen, Z.; Cox, K.S.; Su, H.P.; Callahan, C.; Fridman, A.; Zhang, L.; Patel, S.B.; Cejas, P.J.; Swoyer, R.; et al. A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. *Nat. Commun.* **2019**, *10*, 4153. [\[CrossRef\]](#) [\[PubMed\]](#)
141. Pathania, S.; Rawal, R.K.; Singh, P.K. RdRp (RNA-dependent RNA polymerase): A key target providing anti-virals for the management of various viral diseases. *J. Mol. Struct.* **2022**, *1250*, 131756. [\[CrossRef\]](#) [\[PubMed\]](#)
142. Kumar, R.; Mishra, S.; Shreya; Maurya, S.K. Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses. *RSC Med. Chem.* **2021**, *12*, 306–320. [\[CrossRef\]](#) [\[PubMed\]](#)
143. Beem, M.; Egerer, R.; Anderson, J. Respiratory syncytial virus neutralizing antibodies in persons residing in Chicago, Illinois. *Pediatrics* **1964**, *34*, 761–770. [\[CrossRef\]](#)
144. Bangham, C.R.; Openshaw, P.J.; Ball, L.A.; King, A.M.; Wertz, G.W.; Askonas, B.A. Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. *J. Immunol.* **1986**, *137*, 3973–3977. [\[CrossRef\]](#)
145. Domachowske, J.B.; Rosenberg, H.F. Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment. *Clin. Microbiol. Rev.* **1999**, *12*, 298–309. [\[CrossRef\]](#) [\[PubMed\]](#)
146. Aljabr, W.; Touzelet, O.; Pollakis, G.; Wu, W.; Munday, D.C.; Hughes, M.; Hertz-Fowler, C.; Kenny, J.; Fearn, R.; Barr, J.N.; et al. Investigating the Influence of Ribavirin on Human Respiratory Syncytial Virus RNA Synthesis by Using a High-Resolution Transcriptome Sequencing Approach. *J. Virol.* **2016**, *90*, 4876–4888. [\[CrossRef\]](#) [\[PubMed\]](#)
147. Crotty, S.; Cameron, C.; Andino, R. Ribavirin's antiviral mechanism of action: Lethal mutagenesis? *J. Mol. Med.* **2002**, *80*, 86–95. [\[CrossRef\]](#) [\[PubMed\]](#)
148. Turner, T.L.; Kopp, B.T.; Paul, G.; Landgrave, L.C.; Hayes, D., Jr.; Thompson, R. Respiratory syncytial virus: Current and emerging treatment options. *Clin. Outcomes Res.* **2014**, *6*, 217–225. [\[CrossRef\]](#) [\[PubMed\]](#)
149. Huang, K.; Incognito, L.; Cheng, X.; Ulbrandt, N.D.; Wu, H. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. *J. Virol.* **2010**, *84*, 8132–8140. [\[CrossRef\]](#) [\[PubMed\]](#)
150. Homaira, N.; Rawlinson, W.; Snelling, T.L.; Jaffe, A. Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective. *Int. J. Pediatr.* **2014**, *2014*, 571609. [\[CrossRef\]](#) [\[PubMed\]](#)

151. Vogel, A.M.; Lennon, D.R.; Broadbent, R.; Byrnes, C.A.; Grimwood, K.; Mildenhall, L.; Richardson, V.; Rowley, S. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. *J. Paediatr. Child. Health* **2002**, *38*, 550–554. [[CrossRef](#)] [[PubMed](#)]
152. Mankad, V.S.; Leach, A.; Chang, Y.; Wählby Hamrén, U.; Kiazand, A.; Kubiak, R.J.; Takas, T.; Villafana, T.; Shroff, M. Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials. *Pathogens* **2024**, *13*, 503. [[CrossRef](#)] [[PubMed](#)]
153. Brady, T.; Cayatte, C.; Roe, T.L.; Speer, S.D.; Ji, H.; Machiesky, L.; Zhang, T.; Wilkins, D.; Tuffy, K.M.; Kelly, E.J. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. *Front. Immunol.* **2023**, *14*, 1283120. [[CrossRef](#)] [[PubMed](#)]
154. Available online: <https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers> (accessed on 12 August 2026).
155. Huntley, C.C.; Weiss, W.J.; Gazumyan, A.; Buklan, A.; Feld, B.; Hu, W.; Jones, T.R.; Murphy, T.; Nikitenko, A.A.; O'Hara, B.; et al. RFI-641, a potent respiratory syncytial virus inhibitor. *Antimicrob. Agents Chemother.* **2002**, *46*, 841–847. [[CrossRef](#)] [[PubMed](#)]
156. Sun, Z.; Pan, Y.; Jiang, S.; Lu, L. Respiratory syncytial virus entry inhibitors targeting the F protein. *Viruses* **2013**, *5*, 211–225. [[CrossRef](#)] [[PubMed](#)]
157. Yang, Q.; Xue, B.; Liu, F.; Lu, Y.; Tang, J.; Yan, M.; Wu, Q.; Chen, R.; Zhou, A.; Liu, L.; et al. Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein. *Signal Transduct. Target. Ther.* **2024**, *9*, 144. [[CrossRef](#)] [[PubMed](#)]
158. Trent, T.; Miller, J.J.; Blumer, K.J.; Bowman, G.R. The G Protein Inhibitor YM-254890 is an Allosteric Glue. *J. Mol. Biol.* **2025**, *437*, 169084. [[CrossRef](#)] [[PubMed](#)]
159. Wang, L.; Zhu, Q.; Xiang, K.; Zhang, Y.; Li, B.; Yu, X.; Yang, G.; Liang, C.; Yun, H.; Zhang, M.; et al. Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor. *Antimicrob. Agents Chemother.* **2021**, *65*, 10–1128. [[CrossRef](#)] [[PubMed](#)]
160. Coates, M.; Brookes, D.; Kim, Y.I.; Allen, H.; Fordyce, E.A.F.; Meals, E.A.; Colley, T.; Ciana, C.L.; Parra, G.F.; Sherbukhin, V.; et al. Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor. *Antimicrob. Agents Chemother.* **2017**, *61*, 10–1128. [[CrossRef](#)] [[PubMed](#)]
161. Rhodin, M.H.J.; McAllister, N.V.; Castillo, J.; Noton, S.L.; Fearn, R.; Kim, I.J.; Yu, J.; Blaisdell, T.P.; Panarese, J.; Shook, B.C.; et al. EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. *PLoS Pathog.* **2021**, *17*, e1009428. [[CrossRef](#)] [[PubMed](#)]
162. Chapman, J.; Abbott, E.; Alber, D.G.; Baxter, R.C.; Bithell, S.K.; Henderson, E.A.; Carter, M.C.; Chambers, P.; Chubb, A.; Cockerill, G.S.; et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. *Antimicrob. Agents Chemother.* **2007**, *51*, 3346–3353. [[CrossRef](#)] [[PubMed](#)]
163. Available online: <https://www.merck.com/news/u-s-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-born-during-or-entering-their-fir/> (accessed on 12 August 2026).
164. Panda, S.; Mohakud, N.K.; Pena, L.; Kumar, S. Human metapneumovirus: Review of an important respiratory pathogen. *Int. J. Infect. Dis.* **2014**, *25*, 45–52. [[CrossRef](#)] [[PubMed](#)]
165. Pandey, V.; Shahi, P.; Kolios, G.; Uddin, M.I.; Spathakis, M.; Collins, A.R.; Paspaliaris, V.; Rai, A.K. Human metapneumovirus (hMPV): The virus who came with the common cold. *Infection* **2026**, *54*, 1–13. [[CrossRef](#)] [[PubMed](#)]
166. Dong, Y.; Xie, Z.; Xu, L. Receptors and host factors: Key players in human metapneumovirus infection. *Front. Cell Infect. Microbiol.* **2025**, *15*, 1557880. [[CrossRef](#)] [[PubMed](#)]
167. Bissonnette, M.L.; Connolly, S.A.; Young, D.F.; Randall, R.E.; Paterson, R.G.; Lamb, R.A. Analysis of the pH requirement for membrane fusion of different isolates of the paramyxovirus parainfluenza virus 5. *J. Virol.* **2006**, *80*, 3071–3077. [[CrossRef](#)] [[PubMed](#)]
168. Schowalter, R.M.; Smith, S.E.; Dutch, R.E. Characterization of human metapneumovirus F protein-promoted membrane fusion: Critical roles for proteolytic processing and low pH. *J. Virol.* **2006**, *80*, 10931–10941. [[CrossRef](#)] [[PubMed](#)]
169. Yang, C.F.; Wang, C.K.; Tollefson, S.J.; Lintao, L.D.; Liem, A.; Chu, M.; Williams, J.V. Human metapneumovirus G protein is highly conserved within but not between genetic lineages. *Arch. Virol.* **2013**, *158*, 1245–1252. [[CrossRef](#)] [[PubMed](#)]
170. de Graaf, M.; Osterhaus, A.; Fouchier, R.A.M.; Holmes, E.C. Evolutionary dynamics of human and avian metapneumoviruses. *J. Gen. Virol.* **2008**, *89*, 2933–2942. [[CrossRef](#)] [[PubMed](#)]
171. Van Den Bergh, A.; Bailly, B.; Guillon, P.; von Itzstein, M.; Dirr, L. Antiviral strategies against human metapneumovirus: Targeting the fusion protein. *Antivir. Res.* **2022**, *207*, 105405. [[CrossRef](#)] [[PubMed](#)]
172. Kleiner, V.A.; Fischmann, T.O.; Howe, J.A.; Beshore, D.C.; Eddins, M.J.; Hou, Y.; Mayhood, T.; Klein, D.; Nahas, D.D.; Lucas, B.J.; et al. Conserved allosteric inhibitory site on the respiratory syncytial virus and human metapneumovirus RNA-dependent RNA polymerases. *Commun. Biol.* **2023**, *6*, 649. [[CrossRef](#)] [[PubMed](#)]

173. Huang, J.; Diaz, D.; Mousa, J.J. Antibody recognition of the Pneumovirus fusion protein trimer interface. *PLoS Pathog.* **2020**, *16*, e1008942. [[CrossRef](#)] [[PubMed](#)]
174. Krüger, N.; Laufer, S.A.; Pillaiyar, T. An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities. *Drug Discov. Today* **2025**, *30*, 104364. [[CrossRef](#)] [[PubMed](#)]
175. Kishko, M.; Stuebler, A.; Sasmal, S.; Chan, Y.; Huang, D.; Reyes, C.; Lin, J.; Price, O.; Kume, A.; Zong, K.; et al. A Computationally Designed Prefusion Stabilized Human Metapneumovirus Fusion Protein Vaccine Antigen Elicited a Potent Neutralization Response. *Vaccines* **2025**, *13*, 523. [[CrossRef](#)] [[PubMed](#)]
176. Heim, C.J.; van den Hoogen, B.G.; Dutch, R.E. Human metapneumovirus: Understanding the molecular mechanisms and pathology of infection. *J. Virol.* **2025**, *99*, e0028425. [[CrossRef](#)] [[PubMed](#)]
177. Buchholz, U.J.; Biacchesi, S.; Pham, Q.N.; Tran, K.C.; Yang, L.; Luongo, C.L.; Skiadopoulos, M.H.; Murphy, B.R.; Collins, P.L. Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: Effects on RNA synthesis, attenuation, and immunogenicity. *J. Virol.* **2005**, *79*, 6588–6597. [[CrossRef](#)] [[PubMed](#)]
178. Gálvez, N.M.S.; Andrade, C.A.; Pacheco, G.A.; Soto, J.A.; Stranger, V.; Rivera, T.; Vásquez, A.E.; Kalergis, A.M. Host Components That Modulate the Disease Caused by hMPV. *Viruses* **2021**, *13*, 519. [[CrossRef](#)] [[PubMed](#)]
179. Aerts, L.; Cavanagh, M.H.; Dubois, J.; Carbonneau, J.; Rhéaume, C.; Lavigne, S.; Couture, C.; Hamelin, M.; Boivin, G. Effect of in vitro syncytium formation on the severity of human metapneumovirus disease in a murine model. *PLoS ONE* **2015**, *10*, e0120283. [[CrossRef](#)] [[PubMed](#)]
180. Bao, X.; Liu, T.; Shan, Y.; Li, K.; Garofalo, R.P.; Casola, A. Human metapneumovirus glycoprotein G inhibits innate immune responses. *PLoS Pathog.* **2008**, *4*, e1000077. [[CrossRef](#)] [[PubMed](#)]
181. Velayutham, T.S.; Ivanciuc, T.; Garofalo, R.P.; Casola, A. Role of human metapneumovirus glycoprotein G in modulation of immune responses. *Front. Immunol.* **2022**, *13*, 962925. [[CrossRef](#)] [[PubMed](#)]
182. Principi, N.; Fainardi, V.; Esposito, S. Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment. *Viruses* **2025**, *17*, 1140. [[CrossRef](#)] [[PubMed](#)]
183. Gnanasekaran, S.; Bashir, M.A.; Rajan, A.K.; Prabhat, P. Emerging threat of Human Metapneumovirus (HMPV) and strategies for its containment and control. *Infect. Genet. Evol.* **2025**, *131*, 105758. [[CrossRef](#)] [[PubMed](#)]
184. Dubey, A.; Kumar, M.; Tufail, A.; Dwivedi, V.D. Exploring FDA-approved antiviral drugs for human metapneumovirus treatment: Integrative computational insights. *bioRxiv* **2025**, *bioRxiv*, 2025.01.13.632889. [[CrossRef](#)]
185. Roney, M.; Uddin, M.N.; Mustafa, A.H.; Hamim, S.M.I.; Huq, A.K.M.M.; Aluwi, M.F.F.M. Repurposing FDA-approved asthma drugs against human metapneumovirus: A network pharmacology and molecular simulation approach. *In Silico Res. Biomed.* **2025**, *1*, 100097. [[CrossRef](#)]
186. Miller, R.J.; Mousa, J.J. Structural basis for respiratory syncytial virus and human metapneumovirus neutralization. *Curr. Opin. Virol.* **2023**, *61*, 101337. [[CrossRef](#)] [[PubMed](#)]
187. Pan, J.; Qian, X.; Lattmann, S.; El Sahili, A.; Yeo, T.H.; Jia, H.; Cressey, T.; Ludeke, B.; Noton, S.; Kalocsay, M.; et al. Structure of the human metapneumovirus polymerase phosphoprotein complex. *Nature* **2020**, *577*, 275–279. [[CrossRef](#)] [[PubMed](#)]
188. Basse, V.; Wang, Y.; Rodrigues-Machado, C.; Henry, C.; Richard, C.A.; Leyrat, C.; Galloux, M. Regulation of respiratory syncytial virus nucleoprotein oligomerization by phosphorylation. *J. Biol. Chem.* **2025**, *301*, 108256. [[CrossRef](#)] [[PubMed](#)]
189. Anderson, L.J.; Jadhao, S.J.; Paden, C.R.; Tong, S. Functional Features of the Respiratory Syncytial Virus G Protein. *Viruses* **2021**, *13*, 1214. [[CrossRef](#)] [[PubMed](#)]
190. Elboukari, H.; Ashraf, M. Parainfluenza Virus. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2026.
191. Yea, C.; Cheung, R.; Collins, C.; Adachi, D.; Nishikawa, J.; Tellier, R. The complete sequence of a human parainfluenzavirus 4 genome. *Viruses* **2009**, *1*, 26–41. [[CrossRef](#)] [[PubMed](#)]
192. Yuan, P.; Thompson, T.B.; Wurzburg, B.A.; Paterson, R.G.; Lamb, R.A.; Jardetzky, T.S. Structural studies of the parainfluenza virus 5 hemagglutinin-neuraminidase tetramer in complex with its receptor, sialyllactose. *Structure* **2005**, *13*, 803–815. [[CrossRef](#)] [[PubMed](#)]
193. Xu, R.; Palmer, S.G.; Porotto, M.; Palermo, L.M.; Niewiesk, S.; Wilson, I.A.; Moscona, A. Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo. *mBio* **2013**, *4*, e00803–e00813. [[CrossRef](#)] [[PubMed](#)]
194. Moscona, A.; Peluso, R.W. Relative affinity of the human parainfluenza virus type 3 hemagglutinin-neuraminidase for sialic acid correlates with virus-induced fusion activity. *J. Virol.* **1993**, *67*, 6463–6468. [[CrossRef](#)] [[PubMed](#)]
195. Mizukoshi, F.; Kimura, H.; Sugimoto, S.; Kimura, R.; Nagasawa, N.; Hayashi, Y.; Hashimoto, K.; Hosoya, M.; Shirato, K.; Ryo, A. Molecular Evolutionary Analyses of the Fusion Genes in Human Parainfluenza Virus Type 4. *Microorganisms* **2024**, *12*, 1633. [[CrossRef](#)] [[PubMed](#)]
196. Sugimoto, S.; Kawase, M.; Suwa, R.; Kume, Y.; Chishiki, M.; Ono, T.; Okabe, H.; Norito, S.; Hanaki, K.I.; Hosoya, M.; et al. Comparison of mutations in human parainfluenza viruses during passage in primary human bronchial/tracheal epithelial air-liquid interface cultures and cell lines. *Microbiol. Spectr.* **2024**, *12*, e0116424. [[CrossRef](#)] [[PubMed](#)]

197. Suryadevara, N.; Otrelo-Cardoso, A.R.; Kose, N.; Hu, Y.X.; Binshtein, E.; Wolters, R.M.; Greninger, A.L.; Handal, L.S.; Carnahan, R.H.; Moscona, A.; et al. Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies. *Nat. Microbiol.* **2024**, *9*, 2128–2143. [[CrossRef](#)] [[PubMed](#)]
198. Connolly, S.A.; Leser, G.P.; Yin, H.S.; Jardetzky, T.S.; Lamb, R.A. Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 17903–17908. [[CrossRef](#)] [[PubMed](#)]
199. Welch, B.D.; Liu, Y.; Kors, C.A.; Leser, G.P.; Jardetzky, T.S.; Lamb, R.A. Structure of the cleavage-activated prefusion form of the parainfluenza virus 5 fusion protein. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 16672–16677. [[CrossRef](#)] [[PubMed](#)]
200. Alymova, I.V.; Taylor, G.; Takimoto, T.; Lin, T.H.; Chand, P.; Babu, Y.S.; Li, C.; Xiong, X.; Portner, A. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. *Antimicrob. Agents Chemother.* **2004**, *48*, 1495–1502. [[CrossRef](#)] [[PubMed](#)]
201. Branche, A.R.; Falsey, A.R. Parainfluenza Virus Infection. *Semin. Respir. Crit. Care Med.* **2016**, *37*, 538–554. [[CrossRef](#)] [[PubMed](#)]
202. Luong, Q.X.T.; Hoang, P.T.; Ho, P.T.; Ayun, R.Q.; Lee, T.K.; Lee, S. Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses. *Int. J. Mol. Sci.* **2025**, *26*, 1481. [[CrossRef](#)] [[PubMed](#)]
203. Moscona, A.; Porotto, M.; Palmer, S.; Tai, C.; Aschenbrenner, L.; Triana-Baltzer, G.; Li, Q.X.; Wurtman, D.; Niewiesk, S.; Fang, F. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. *J. Infect. Dis.* **2010**, *202*, 234–241. [[CrossRef](#)] [[PubMed](#)]
204. Malakhov, M.P.; Aschenbrenner, L.M.; Smee, D.F.; Wandersee, M.K.; Sidwell, R.W.; Gubareva, L.V.; Mishin, V.P.; Hayden, F.G.; Kim, D.H.; Ing, A.; et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. *Antimicrob. Agents Chemother.* **2006**, *50*, 1470–1479. [[CrossRef](#)] [[PubMed](#)]
205. Palermo, L.M.; Porotto, M.; Yokoyama, C.C.; Palmer, S.G.; Mungall, B.A.; Greengard, O.; Niewiesk, S.; Moscona, A. Human parainfluenza virus infection of the airway epithelium: Viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity. *J. Virol.* **2009**, *83*, 6900–6908. [[CrossRef](#)] [[PubMed](#)]
206. Te Velthuis, A.J.W.; Grimes, J.M.; Fodor, E. Structural insights into RNA polymerases of negative-sense RNA viruses. *Nat. Rev. Microbiol.* **2021**, *19*, 303–318. [[CrossRef](#)] [[PubMed](#)]
207. Malur, A.G.; Choudhary, S.K.; De, B.P.; Banerjee, A.K. Role of a highly conserved NH(2)-terminal domain of the human parainfluenza virus type 3 RNA polymerase. *J. Virol.* **2002**, *76*, 8101–8109. [[CrossRef](#)] [[PubMed](#)]
208. Palmer, S.G.; DeVito, I.; Jenkins, S.G.; Niewiesk, S.; Porotto, M.; Moscona, A. Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for in vivo infection. *J. Virol.* **2014**, *88*, 13495–13502. [[CrossRef](#)] [[PubMed](#)]
209. Shirai, T.; Mizukoshi, F.; Kimura, R.; Matsuoka, R.; Sada, M.; Shirato, K.; Ishii, H.; Ryo, A.; Kimura, H. Molecular Evolution of the Fusion (F) Genes in Human Parainfluenza Virus Type 2. *Microorganisms* **2025**, *13*, 399. [[CrossRef](#)] [[PubMed](#)]
210. Nishio, M.; Tsurudome, M.; Garcin, D.; Komada, H.; Ito, M.; Le Mercier, P.; Nosaka, T.; Kolakofsky, D. Human parainfluenza virus type 2 L protein regions required for interaction with other viral proteins and mRNA capping. *J. Virol.* **2011**, *85*, 725–732. [[CrossRef](#)] [[PubMed](#)]
211. Lin, Y.; Jiang, J.; Li, C.; Zhu, C.; Sun, L.; Mu, M.; Guo, Y.; Dong, M.; Zhao, L.; Zhang, F.; et al. Evolutionary Dynamics of Human Parainfluenza Virus Type 1 Based on the Hemagglutinin-Neuraminidase Gene. *J. Med. Virol.* **2025**, *97*, e70632. [[CrossRef](#)] [[PubMed](#)]
212. Pawełczyk, M.; Kowalski, M.L. The Role of Human Parainfluenza Virus Infections in the Immunopathology of the Respiratory Tract. *Curr. Allergy Asthma Rep.* **2017**, *17*, 16. [[CrossRef](#)] [[PubMed](#)]
213. Plattet, P.; Alves, L.; Herren, M.; Aguilar, H.C. Measles Virus Fusion Protein: Structure, Function and Inhibition. *Viruses* **2016**, *8*, 112. [[CrossRef](#)] [[PubMed](#)]
214. Wang, D.; Yang, G.; Liu, B. Structure of the measles virus ternary polymerase complex. *Nat. Commun.* **2025**, *16*, 3819. [[CrossRef](#)] [[PubMed](#)]
215. Phan, M.V.T.; Schapendonk, C.M.E.; Oude Munnink, B.B.; Koopmans, M.P.G.; de Swart, R.L.; Cotten, M. Complete Genome Sequences of Six Measles Virus Strains. *Genome Announc.* **2018**, *6*, e00184–18. [[CrossRef](#)] [[PubMed](#)]
216. Lin, L.T.; Richardson, C.D. The Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) Protein. *Viruses* **2016**, *8*, 250. [[CrossRef](#)] [[PubMed](#)]
217. Hu, C.; Zhang, P.; Liu, X.; Qi, Y.; Zou, T.; Xu, Q. Characterization of a region involved in binding of measles virus H protein and its receptor SLAM (CD150). *Biochem. Biophys. Res. Commun.* **2004**, *316*, 698–704. [[CrossRef](#)] [[PubMed](#)]
218. Welstead, G.G.; Hsu, E.C.; Iorio, C.; Bolotin, S.; Richardson, C.D. Mechanism of CD150 (SLAM) down regulation from the host cell surface by measles virus hemagglutinin protein. *J. Virol.* **2004**, *78*, 9666–9674. [[CrossRef](#)] [[PubMed](#)]
219. Parkman, P.D. Togaviruses: Rubella Virus. In *Medical Microbiology*, 4th ed.; Baron, S., Ed.; University of Texas Medical Branch at Galveston: Galveston, TX, USA, 1996.
220. Lambert, N.; Strebel, P.; Orenstein, W.; Icenogle, J.; Poland, G.A. Rubella. *Lancet* **2015**, *385*, 2297–2307. [[CrossRef](#)] [[PubMed](#)]

221. Mankertz, A.; Chen, M.H.; Goldberg, T.L.; Hübschen, J.M.; Pfaff, F.; Ulrich, R.G.; Ictv Report, C. ICTV Virus Taxonomy Profile: Matonaviridae 2022. *J. Gen. Virol.* **2022**, *103*, 001817. [\[CrossRef\]](#) [\[PubMed\]](#)
222. Mangala Prasad, V.; Willows, S.D.; Fokine, A.; Battisti, A.J.; Sun, S.; Plevka, P.; Hobman, T.C.; Rossmann, M.G. Rubella virus capsid protein structure and its role in virus assembly and infection. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 20105–20110. [\[CrossRef\]](#) [\[PubMed\]](#)
223. Yang, D.; Hwang, D.; Qiu, Z.; Gillam, S. Effects of mutations in the rubella virus E1 glycoprotein on E1–E2 interaction and membrane fusion activity. *J. Virol.* **1998**, *72*, 8747–8755. [\[CrossRef\]](#) [\[PubMed\]](#)
224. Das, P.K.; Kielian, M. Molecular and Structural Insights into the Life Cycle of Rubella Virus. *J. Virol.* **2021**, *95*, 10–1128. [\[CrossRef\]](#) [\[PubMed\]](#)
225. Lee, J.Y.; Bowden, D.S. Rubella virus replication and links to teratogenicity. *Clin. Microbiol. Rev.* **2000**, *13*, 571–587. [\[CrossRef\]](#) [\[PubMed\]](#)
226. Chen, M.H.; Icenogle, J. Molecular Virology of Rubella Virus. In *Rubella Viruses*; Banatvala, J., Peckham, C., Eds.; Perspectives in Medical Virology; Elsevier: Amsterdam, The Netherlands, 2007; Volume 15, pp. 1–8.
227. Ayata, M.; Takeuchi, K.; Takeda, M.; Ohgimoto, S.; Kato, S.; Sharma, L.B.; Tanaka, M.; Kuwamura, M.; Ishida, H.; Ogura, H. The F gene of the Osaka-2 strain of measles virus derived from a case of subacute sclerosing panencephalitis is a major determinant of neurovirulence. *J. Virol.* **2010**, *84*, 11189–11199. [\[CrossRef\]](#) [\[PubMed\]](#)
228. Zhu, Z.; Chen, M.H.; Abernathy, E.; Icenogle, J.; Zhou, S.; Wang, C.; Zhao, C.; Wang, Y.; Chen, H.; Si, Y.; et al. Analysis of complete genomes of the rubella virus genotypes 1E and 2B which circulated in China, 2000–2013. *Sci. Rep.* **2016**, *6*, 39025. [\[CrossRef\]](#) [\[PubMed\]](#)
229. Das, P.K.; Gonzalez, P.A.; Jangra, R.K.; Yin, P.; Kielian, M. A single-point mutation in the rubella virus E1 glycoprotein promotes rescue of recombinant vesicular stomatitis virus. *mBio* **2024**, *15*, e0237323. [\[CrossRef\]](#) [\[PubMed\]](#)
230. Kweder, H.; Ainouze, M.; Cosby, S.L.; Muller, C.P.; Lévy, C.; Verhoeven, E.; Cosset, F.L.; Manet, E.; Buckland, R. Mutations in the H, F, or M Proteins Can Facilitate Resistance of Measles Virus to Neutralizing Human Anti-MV Sera. *Adv. Virol.* **2014**, *2014*, 205617. [\[CrossRef\]](#) [\[PubMed\]](#)
231. Wang, D.; Bu, F.; Yang, G.; Liu, B. Structural basis of measles virus polymerase inhibition by nonnucleoside inhibitor ERDRP-0519. *Nat. Commun.* **2025**, *16*, 9061. [\[CrossRef\]](#) [\[PubMed\]](#)
232. Dittmar, M.; Whig, K.; Miller, J.; Kamalia, B.; Suppiah, S.; Perelygina, L.; Sullivan, K.E.; Schultz, D.C.; Cherry, S. Nucleoside analogs NM107 and AT-527 are antiviral against rubella virus. *PNAS Nexus* **2023**, *2*, pgad256. [\[CrossRef\]](#) [\[PubMed\]](#)
233. Doyle, J.; Prussia, A.; White, L.K.; Sun, A.; Liotta, D.C.; Snyder, J.P.; Compans, R.W.; Plemper, R.K. Two domains that control prefusion stability and transport competence of the measles virus fusion protein. *J. Virol.* **2006**, *80*, 1524–1536. [\[CrossRef\]](#) [\[PubMed\]](#)
234. Adeoye, A.F.; Umoru, D.O.; Gomez, O.O.; Onifade, I.A.; Akangbe, B.O.; Elechi, U.S.; Barrah, V.U. The 2025 United States Measles Crisis: When Vaccine Hesitancy Meets Reality. *Cureus* **2025**, *17*, e88196. [\[CrossRef\]](#) [\[PubMed\]](#)
235. Gao, Z.; Sasaki, J.; Suzuki, T.; Sando, S.; Hashiguchi, T.; Morimoto, J. A Short Peptide Inhibitor of Measles Virus Fusion Protein that Exhibits Passive Membrane Permeability. *ChemMedChem* **2025**, *20*, e202500532. [\[CrossRef\]](#) [\[PubMed\]](#)
236. Düzgüneş, N.; Fernandez-Fuentes, N.; Konopka, K. Inhibition of Viral Membrane Fusion by Peptides and Approaches to Peptide Design. *Pathogens* **2021**, *10*, 1599. [\[CrossRef\]](#) [\[PubMed\]](#)
237. Available online: <https://www.cdc.gov/rubella/hcp/clinical-overview/index.html> (accessed on 12 August 2026).
238. Perelygina, L.; Hautala, T.; Seppänen, M.; Adebayo, A.; Sullivan, K.E.; Icenogle, J. Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency. *Antivir. Res.* **2017**, *147*, 58–66. [\[CrossRef\]](#) [\[PubMed\]](#)
239. Umino, Y.; Tashiro, M. Inhibition of rubella virus growth by Fungizone. *Vaccine* **2001**, *19*, 1369–1372. [\[CrossRef\]](#) [\[PubMed\]](#)
240. Hashiguchi, T.; Fukuda, Y.; Matsuoka, R.; Kuroda, D.; Kubota, M.; Shirogane, Y.; Watanabe, S.; Tsumoto, K.; Kohda, D.; Plemper, R.K.; et al. Structures of the prefusion form of measles virus fusion protein in complex with inhibitors. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 2496–2501. [\[CrossRef\]](#) [\[PubMed\]](#)
241. Fukuhara, H.; Mwaba, M.H.; Maenaka, K. Structural characteristics of measles virus entry. *Curr. Opin. Virol.* **2020**, *41*, 52–58. [\[CrossRef\]](#) [\[PubMed\]](#)
242. Navaratnarajah, C.K.; Leonard, V.H.; Cattaneo, R. Measles virus glycoprotein complex assembly, receptor attachment, and cell entry. *Curr. Top. Microbiol. Immunol.* **2009**, *329*, 59–76. [\[CrossRef\]](#) [\[PubMed\]](#)
243. Nakatsu, Y.; Takeda, M.; Ohno, S.; Shirogane, Y.; Iwasaki, M.; Yanagi, Y. Measles virus circumvents the host interferon response by different actions of the C and V proteins. *J. Virol.* **2008**, *82*, 8296–8306. [\[CrossRef\]](#) [\[PubMed\]](#)
244. Jacobs, S.E.; Lamson, D.M.; St George, K.; Walsh, T.J. Human rhinoviruses. *Clin. Microbiol. Rev.* **2013**, *26*, 135–162. [\[CrossRef\]](#) [\[PubMed\]](#)
245. Wang, Q.M.; Chen, S.H. Human rhinovirus 3C protease as a potential target for the development of antiviral agents. *Curr. Protein Pept. Sci.* **2007**, *8*, 19–27. [\[CrossRef\]](#) [\[PubMed\]](#)

246. Murer, L.; Petkidis, A.; Vallet, T.; Vignuzzi, M.; Greber, U.F. Chemical Evolution of Rhinovirus Identifies Capsid-Destabilizing Mutations Driving Low-pH-Independent Genome Uncoating. *J. Virol.* **2022**, *96*, e0106021. [CrossRef] [PubMed]
247. Binford, S.L.; Maldonado, F.; Brothers, M.A.; Weady, P.T.; Zalman, L.S.; Meador, J.W., 3rd; Matthews, D.A.; Patick, A.K. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. *Antimicrob. Agents Chemother.* **2005**, *49*, 619–626. [CrossRef] [PubMed]
248. Appleby, T.C.; Luecke, H.; Shim, J.H.; Wu, J.Z.; Cheney, I.W.; Zhong, W.; Vogeley, L.; Hong, Z.; Yao, N. Crystal structure of complete rhinovirus RNA polymerase suggests front loading of protein primer. *J. Virol.* **2005**, *79*, 277–288. [CrossRef] [PubMed]
249. Ledford, R.M.; Patel, N.R.; Demenczuk, T.M.; Watanyar, A.; Herbertz, T.; Collett, M.S.; Pevear, D.C. VP1 sequencing of all human rhinovirus serotypes: Insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. *J. Virol.* **2004**, *78*, 3663–3674. [CrossRef] [PubMed]
250. Gil-Cantero, D.; Mata, C.P.; Valiente, L.; Rodríguez-Huete, A.; Valbuena, A.; Twarock, R.; Stockley, P.G.; Mateu, M.G.; Castón, J.R. Cryo-EM of human rhinovirus reveals capsid-RNA duplex interactions that provide insights into virus assembly and genome uncoating. *Commun. Biol.* **2024**, *7*, 1501. [CrossRef] [PubMed]
251. Nirwan, S.; Kakkar, R. Rhinovirus RNA Polymerase: Structure, Function, and Inhibitors. *Viral Polym.* **2018**, *2019*, 301–331. [CrossRef] [PubMed Central]
252. Basnet, S.; Palmenberg, A.C.; Gern, J.E. Rhinoviruses and Their Receptors. *Chest* **2019**, *155*, 1018–1025. [CrossRef] [PubMed]
253. Zhang, S.; Zong, K.; Ruan, J.; Liu, X.; Zhao, X.; Zhang, Y.; Hu, C.; Li, X. Discovery of non-covalent rhinovirus 3Cpro inhibitors by molecular docking, in vitro assays, molecular dynamics simulations and DFT analyses. *Front. Pharmacol.* **2025**, *16*, 1560571. [CrossRef] [PubMed]
254. Blaas, D.; Fuchs, R. Mechanism of human rhinovirus infections. *Mol. Cell Pediatr.* **2016**, *3*, 21. [CrossRef] [PubMed]
255. Moreira, E.A.; Yamauchi, Y.; Matthias, P. How Influenza Virus Uses Host Cell Pathways during Uncoating. *Cells* **2021**, *10*, 1722. [CrossRef] [PubMed]
256. Romero, J.R. Pleconaril: A novel antipicornaviral drug. *Expert Opin. Investig. Drugs* **2001**, *10*, 369–379. [CrossRef] [PubMed]
257. Available online: <https://www.sciencedirect.com/science/article/pii/B9780444537171001529> (accessed on 12 August 2026).
258. Coultas, J.A.; Cafferkey, J.; Mallia, P.; Johnston, S.L. Experimental Antiviral Therapeutic Studies for Human Rhinovirus Infections. *J. Exp. Pharmacol.* **2021**, *13*, 645–659. [CrossRef] [PubMed]
259. Binford, S.L.; Weady, P.T.; Maldonado, F.; Brothers, M.A.; Matthews, D.A.; Patick, A.K. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. *Antimicrob. Agents Chemother.* **2007**, *51*, 4366–4373. [CrossRef] [PubMed]
260. Marlin, S.D.; Staunton, D.E.; Springer, T.A.; Stratowa, C.; Sommergruber, W.; Merluzzi, V.J. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. *Nature* **1990**, *344*, 70–72. [CrossRef] [PubMed]
261. Hoover-Litty, H.; Greve, J.M. Formation of rhinovirus-soluble ICAM-1 complexes and conformational changes in the virion. *J. Virol.* **1993**, *67*, 390–397. [CrossRef] [PubMed]
262. Casanova, V.; Sousa, F.H.; Stevens, C.; Barlow, P.G. Antiviral therapeutic approaches for human rhinovirus infections. *Future Virol.* **2018**, *13*, 505–518. [CrossRef] [PubMed]
263. Ljubin-Sternak, S.; Meštrović, T. Rhinovirus-A True Respiratory Threat or a Common Inconvenience of Childhood? *Viruses* **2023**, *15*, 825. [CrossRef] [PubMed]
264. Matsui, T.; Fujita, M.; Ishibashi, Y.; Nomanbhoy, T.; Rosenblum, J.S.; Nagasawa, M. 134. KRP-A218, an Orally Active and Selective PI4KB Inhibitor with Broad-Spectrum Anti-Rhinovirus Activity, Has Potent Therapeutic Antiviral Activity In vivo. *Open Forum Infect. Dis.* **2021**, *8*, S82. [CrossRef]
265. Amineva, S.P.; Aminev, A.G.; Palmenberg, A.C.; Gern, J.E. Rhinovirus 3C protease precursors 3CD and 3CD' localize to the nuclei of infected cells. *J. Gen. Virol.* **2004**, *85*, 2969–2979. [CrossRef] [PubMed]
266. Real-Hohn, A.; Blaas, D. Rhinovirus Inhibitors: Including a New Target, the Viral RNA. *Viruses* **2021**, *13*, 1784. [CrossRef] [PubMed]
267. Skern, T.; Torgersen, H.; Auer, H.; Kuechler, E.; Blaas, D. Human rhinovirus mutants resistant to low pH. *Virology* **1991**, *183*, 757–763. [CrossRef] [PubMed]
268. Shukla, S.D.; Shastri, M.D.; Vanka, S.K.; Jha, N.K.; Dureja, H.; Gupta, G.; Chellappan, D.K.; Oliver, B.G.; Dua, K.; Walters, E.H. Targeting intercellular adhesion molecule-1 (ICAM-1) to reduce rhinovirus-induced acute exacerbations in chronic respiratory diseases. *Inflammopharmacology* **2022**, *30*, 725–735. [CrossRef] [PubMed]
269. Kennedy, M.A.; Parks, R.J. Adenovirus virion stability and the viral genome: Size matters. *Mol. Ther.* **2009**, *17*, 1664–1666. [CrossRef] [PubMed]
270. Jason, G.; Smith, C.M.W.; Stewart, P.L.; Nemerow, G.R. Adenovirus. *Curr. Top. Microbiol. Immunol.* **2010**, *343*, 195–224. [CrossRef] [PubMed] [PubMed Central]
271. Lynch, J.P., 3rd; Kajon, A.E. Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention. *Semin. Respir. Crit. Care Med.* **2016**, *37*, 586–602. [CrossRef] [PubMed]

272. Kunz, A.N.; Ottolini, M. The role of adenovirus in respiratory tract infections. *Curr. Infect. Dis. Rep.* **2010**, *12*, 81–87. [[CrossRef](#)] [[PubMed](#)]
273. Nestić, D.; Božinović, K.; Pehar, I.; Wallace, R.; Parker, A.L.; Majhen, D. The Revolving Door of Adenovirus Cell Entry: Not All Pathways Are Equal. *Pharmaceutics* **2021**, *13*, 1585. [[CrossRef](#)] [[PubMed](#)]
274. Pinkert, S.; Röger, C.; Kurreck, J.; Bergelson, J.M.; Fechner, H. The Coxsackievirus and Adenovirus Receptor: Glycosylation and the Extracellular D2 Domain Are Not Required for Coxsackievirus B3 Infection. *J. Virol.* **2016**, *90*, 5601–5610. [[CrossRef](#)] [[PubMed](#)]
275. Bewley, M.C.; Springer, K.; Zhang, Y.B.; Freimuth, P.; Flanagan, J.M. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. *Science* **1999**, *286*, 1579–1583. [[CrossRef](#)] [[PubMed](#)]
276. Meier, O.; Greber, U.F. Adenovirus endocytosis. *J. Gene Med.* **2004**, *6*, S152–S163. [[CrossRef](#)] [[PubMed](#)]
277. Hussain, K.M.; Leong, K.L.; Ng, M.M.; Chu, J.J. The essential role of clathrin-mediated endocytosis in the infectious entry of human enterovirus 71. *J. Biol. Chem.* **2011**, *286*, 309–321. [[CrossRef](#)] [[PubMed](#)]
278. Shankar, S.; Pan, J.; Yang, P.; Bian, Y.; Oroszlán, G.; Yu, Z.; Mukherjee, P.; Filman, D.J.; Hogle, J.M.; Shekhar, M.; et al. Viral DNA polymerase structures reveal mechanisms of antiviral drug resistance. *Cell* **2024**, *187*, 5572–5586.e5515. [[CrossRef](#)] [[PubMed](#)]
279. Terrell, S.L.; Pesola, J.M.; Coen, D.M. Roles of conserved residues within the pre-NH2-terminal domain of herpes simplex virus 1 DNA polymerase in replication and latency in mice. *J. Gen. Virol.* **2014**, *95*, 940–947. [[CrossRef](#)] [[PubMed](#)]
280. Krasnykh, V.; Belousova, N.; Korokhov, N.; Mikheeva, G.; Curiel, D.T. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. *J. Virol.* **2001**, *75*, 4176–4183. [[CrossRef](#)] [[PubMed](#)]
281. Bauer, U.; Flunker, G.; Bruss, K.; Kallwellis, K.; Liebermann, H.; Luettich, T.; Motz, M.; Seidel, W. Detection of antibodies against adenovirus protein IX, fiber, and hexon in human sera by immunoblot assay. *J. Clin. Microbiol.* **2005**, *43*, 4426–4433. [[CrossRef](#)] [[PubMed](#)]
282. Pérez-Berná, A.J.; Marabini, R.; Scheres, S.H.; Menéndez-Conejero, R.; Dmitriev, I.P.; Curiel, D.T.; Mangel, W.F.; Flint, S.J.; San Martín, C. Structure and uncoating of immature adenovirus. *J. Mol. Biol.* **2009**, *392*, 547–557. [[CrossRef](#)]
283. Medina-Kauwe, L.K. Development of adenovirus capsid proteins for targeted therapeutic delivery. *Ther. Deliv.* **2013**, *4*, 267–277. [[CrossRef](#)] [[PubMed](#)]
284. Waye, M.M.Y.; Sing, C.W. Anti-Viral Drugs for Human Adenoviruses. *Pharmaceutics* **2010**, *3*, 3343–3354. [[CrossRef](#)]
285. Stern, A.; Alonso, C.D.; Garcia-Vidal, C.; Cardozo, C.; Slavin, M.; Yong, M.K.; Ho, S.A.; Mehta Steinke, S.; Avery, R.K.; Koehler, P.; et al. Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: A retrospective multicentre cohort study. *J. Antimicrob. Chemother.* **2021**, *76*, 3020–3028. [[CrossRef](#)]
286. Vittecoq, D.; Dumitrescu, L.; Beauflis, H.; Deray, G. Fanconi syndrome associated with cidofovir therapy. *Antimicrob. Agents Chemother.* **1997**, *41*, 1846. [[CrossRef](#)] [[PubMed](#)]
287. Meier, P.; Dautheville-Guibal, S.; Ronco, P.M.; Rossert, J. Cidofovir-induced end-stage renal failure. *Nephrol. Dial. Transplant.* **2002**, *17*, 148–149. [[CrossRef](#)] [[PubMed](#)]
288. Verhees, F.; Legemaate, D.; Demers, I.; Jacobs, R.; Haakma, W.E.; Rousch, M.; Kremer, B.; Speel, E.J. The Antiviral Agent Cidofovir Induces DNA Damage and Mitotic Catastrophe in HPV-Positive and -Negative Head and Neck Squamous Cell Carcinomas In Vitro. *Cancers* **2019**, *11*, 919. [[CrossRef](#)] [[PubMed](#)]
289. Ying, B.; Tollefson, A.E.; Spencer, J.F.; Balakrishnan, L.; Dewhurst, S.; Capella, C.; Buller, R.M.; Toth, K.; Wold, W.S. Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters. *Antimicrob. Agents Chemother.* **2014**, *58*, 7171–7181. [[CrossRef](#)] [[PubMed](#)]
290. Zhang, Y.; Wan, Y.; Guo, C.; Zhu, Z.; Qiu, C.; Lu, J.; Zhou, Y.; Zheng, J.; Dai, F.; Cheng, X.; et al. Novel derivatives of brincidofovir and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine inhibit orthopoxviruses and human adenoviruses more potently than brincidofovir. *Signal Transduct. Target. Ther.* **2025**, *10*, 114. [[CrossRef](#)] [[PubMed](#)]
291. Alvarez-Cardona, J.J.; Whited, L.K.; Chemaly, R.F. Brincidofovir: Understanding its unique profile and potential role against adenovirus and other viral infections. *Future Microbiol.* **2020**, *15*, 389–400. [[CrossRef](#)] [[PubMed](#)]
292. Wang, B.; Cao, B.; Bei, Z.C.; Xu, L.; Zhang, D.; Zhao, L.; Song, Y.; Wang, H. Disulfide-incorporated lipid prodrugs of cidofovir: Synthesis, antiviral activity, and release mechanism. *Eur. J. Med. Chem.* **2023**, *258*, 115601. [[CrossRef](#)] [[PubMed](#)]
293. Georgi, F.; Andriasyan, V.; Witte, R.; Murer, L.; Hemmi, S.; Yu, L.; Grove, M.; Meili, N.; Kuttler, F.; Yakimovich, A.; et al. The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus. *Antimicrob. Agents Chemother.* **2020**, *64*, 10–1128. [[CrossRef](#)]
294. O'Shea, C.; Klupsch, K.; Choi, S.; Bagus, B.; Soria, C.; Shen, J.; McCormick, F.; Stokoe, D. Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. *EMBO J.* **2005**, *24*, 1211–1221. [[CrossRef](#)] [[PubMed](#)]
295. Dalidowska, I.; Gazi, O.; Sulejczak, D.; Przybylski, M.; Bieganski, P. Heat Shock Protein 90 Chaperones E1A Early Protein of Adenovirus 5 and Is Essential for Replication of the Virus. *Int. J. Mol. Sci.* **2021**, *22*, 2020. [[CrossRef](#)] [[PubMed](#)]
296. Bruder, J.T.; Kovesdi, I. Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. *J. Virol.* **1997**, *71*, 398–404. [[CrossRef](#)] [[PubMed](#)]

297. Liu, M.; Jiang, L.; Cao, W.; Wu, J.; Chen, X. Identification of Inhibitors and Drug Targets for Human Adenovirus Infections. *Viruses* **2022**, *14*, 959. [[CrossRef](#)] [[PubMed](#)]
298. Jeyaraj, G.; Rajendran, A.K.; Sathishkumar, K.; Almutairi, B.O.; Vadivelu, A.; Chokkakula, S.; Tu, Y.; Xie, W. High-resolution protein modeling through Cryo-EM and AI: Current trends and future perspectives—A review. *Front. Mol. Biosci.* **2025**, *12*, 1688455. [[CrossRef](#)] [[PubMed](#)]
299. Saha, B.; Wong, C.M.; Parks, R.J. The adenovirus genome contributes to the structural stability of the virion. *Viruses* **2014**, *6*, 3563–3583. [[CrossRef](#)] [[PubMed](#)]
300. Robinson, C.M.; Singh, G.; Lee, J.Y.; Dehghan, S.; Rajaiya, J.; Liu, E.B.; Yousuf, M.A.; Betensky, R.A.; Jones, M.S.; Dyer, D.W.; et al. Molecular evolution of human adenoviruses. *Sci. Rep.* **2013**, *3*, 1812. [[CrossRef](#)] [[PubMed](#)]
301. Gallardo, J.; Pérez-Illana, M.; Martín-González, N.; San Martín, C. Adenovirus Structure: What Is New? *Int. J. Mol. Sci.* **2021**, *22*, 5240. [[CrossRef](#)]
302. Ebner, K.; Pinsker, W.; Lion, T. Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: Phylogenetic, taxonomic, and clinical implications. *J. Virol.* **2005**, *79*, 12635–12642. [[CrossRef](#)] [[PubMed](#)]
303. Baker, A.T.; Greenshields-Watson, A.; Coughlan, L.; Davies, J.A.; Uusi-Kerttula, H.; Cole, D.K.; Rizkallah, P.J.; Parker, A.L. Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. *Nat. Commun.* **2019**, *10*, 741. [[CrossRef](#)] [[PubMed](#)]
304. Saha, B.; Parks, R.J. Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cells. *PLoS ONE* **2017**, *12*, e0181012. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.